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ABSTRACT 
A macromolecule that specifically binds R5020 may be present in 
3 
rat liver cytosol. Incubations were performed at 4 nM H-R5020 and 
20 nM "^H-R5020. With a 30% ammonium sulfate (AS) fractionation, 
superior recovery of specific binding as a fraction of total binding 
3 
occurred at 20 nM H-R5020. Ammonium sulfate fractionation was 
employed to attempt to partially purify and to remove metabolizing 
enzymes that may be present in liver cytosol. Maximum recovery of 
specific binding, 170 fmoles/g liver, was found with a 40% ammonium 
sulfate fraction. In this experimental series the amount of R5020 
specific binding found was 34 to 170 fmoles/g tissue or 1.8 to 8.8 
fmoles/mg cytosol protein (with 40% ammonium sulfate fractionation 
3 
and incubating concentration of H-R5020 = 20 nM). When cytosol, 
3 
purified or unpurified, was incubated at 4 or 20 nM H-R5020 with a 50 
fold excess of various steroids, a pattern was found in ability to 
compete for specific sites, R5020>progesterone > R1881 > cortisol, 
greatest to least. Priming with 100 yg/day of ethinyl estradiol for 3 days per 
rat produced no marked change in amount of R5020-specific macromolecular 
binding. A similar level of R5020-specific macromolecular binding was 
found, 50.3 fmoles/g cells, when isolated, intact liver parenchymal 
cells were incubated at 0°C with steroid prior to homogenization. For 
3 
the majority of AS fractions of liver cytosol no H-R5020 metabolizing 
activity was detectable. R5020 specific binding was found in unpurified 
rat uterine cytosol in amounts ranging from 500 to 6,160 fmoles/g uterus. 
3 
At an incubating concentration of 20 nM H-R5020, R5020 specific binding 
in unpurified uterine cytosol was 159 fmoles/mg cytosol protein. These 
results, though not conclusive,indicate that low levels of a progestin- 
1 
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INTRODUCTION 
Steroid hormone contraceptives have become today among 
the most widely used of medications. It is estimated that 
worldwide there are more than 50 million users (1). 
Numerous studies have established the high reliability, 
especially of combined oral contraceptives. However, since the 
introduction of these agents, a number of side effects has 
come to the attention of the medical world. These in¬ 
clude thromboembolic disease, stroke, myocardial infarction, 
and a number of others. Many of these side effects may in 
fact be mediated by an estrogen receptor in liver. Eisenfeld 
et al.(2) theorize that an estrogen interaction in the liver 
may explain metabolic changes observed in association with 
estrogen administration as well as having the virtue of 
simplifying estrogen interaction in mediating side effects 
to a single organ. These investigators go on to cite studies 
( 3,4,5 ) detailing the demonstration of an estrogen receptor 
in mammalian (rat) liver cytosol. 
This thesis project was generated with the idea of 
applying similar logic to the progestagenic component of 
oral contraceptives. Not all of the side effects associated 
with oral contraceptive use are attributable to the estro¬ 
genic component. Though conflicting, data in the literature 
suggests that the progestagenic component may be closely 
3 
. 
associated with the appearance of certain side effects. 
Could the appearance of these side effects be mediated by 
a liver progesterone receptor? 
This paper will consist first of a review 
of the literature pertaining to the role of progestagenic 
agents in mediating oral contraceptive side effects. Also 
included will be a summary of some of the characteristics of 
progesterone receptors and where they have been found. 
Then a laboratory study, undertaken to isolate a possible liver 
progesterone receptor, will be described. This will be 
followed by a discussion of the results with reference to 
relevant literature. 
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LITERATURE 
Part A General Side Effects of Hormonal Contraceptives: 
Brief Review 
Use of steroid hormone contraceptives has been associ¬ 
ated with a myriad of side effects. These are well reviewed in 
Durand et al. (6), McQueen (7), and Andrews (8). A principal 
category is thromboembolic disease. A number of studies, including 
a large prospective study reported in 1974 by the Royal College 
of General Practitioners (9), have documented a relationship 
between oral contraception and deep-vein thrombosis. The 
same study by the RCGP and one by the Boston-based Collabora¬ 
tive Group for the Study of Stroke in Young Women (10) re¬ 
port increased risk of cerebrovascular disease among oral 
contraceptive users. According to the RCGP study, excess 
mortality rate among contraceptive users for diseases of the 
circulatory system increases with age, cigarette smoking, and 
duration of oral contraceptive use (11). Users of oral contra¬ 
ceptives appear also to be at increased risk for myocardial 
infarction, a serious sequela of coronary artery disease. This 
is documented in the RCGP study (11) as well as in another pro¬ 
spective study by Vessey et al. (12). Jick et al. (13) in a 
retrospective case control study found a strong positive associa¬ 
tion between MI and age, oral contraceptive and noncontra¬ 
ceptive estrogen use, cigarette smoking, and the presence 
of predisposing medical conditions such as hypertension, dia¬ 
betes, and past MI. McQueen in his review (7) reports that a 
variety of lesions continues to be related in individual case 
5 
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reports or reports of restricted series. These include peri¬ 
pheral arterial thrombosis, mesenteric and intestinal occlusion, 
retinal vessel occlusion, pancreatic artery thrombosis, renal 
artery thrombosis, and aortoiliac arterial occlusion. 
Many studies seem to implicate oral contraceptives in modi¬ 
fication of blood clotting parameters and fibrinolysis. 
Elevations in the levels of clotting factors VII, VIII, IX, 
and X, increased fibrinolytic activity, and increased platelet 
sensitivity to adenosine diphosphate have been reported (6). 
The role played by these changes in altering hemostasis is 
not well defined because much of the data is conflicting and 
many of the studies are not statistically adequate. Some data 
suggests that progestins may play a role in generation of 
clotting abnormalities. 
Oral contraceptives were shown by the RCGP prospective 
study (9) to be a cause of hypertension. Other case control 
retrospective studies are consistent with this in revealing 
an association between oral contraceptive use and hypertension. 
The dose of one type of progestogen and duration of use are 
correlated with increased incidence of hypertension (9). 
Lipid metabolism has been reported to be affected by 
oral contraceptive use. The data here are not definite, being most 
ly small series and case reports. Certain progestogens may 
enhance triglyceride and free fatty acid (FFA) concentrations. 
This area is reviewed in McQueen (7). Hormonal contraceptives 
may also adversely affect carbohydrate metabolism. Abnormalities 
in oral, intravenous, and cortisone-stimu1 ated glucose tolerance 
6 
‘ 
t ■ 
curves have been reported in oral contraceptive users. Again, 
available data are conflicting. The progestogen component of 
the pill may play a major role in causing these abnormalities (7). 
Oral contraceptive users my be at increased risk for 
hepatic tumors, hepatic cell adenomas, focal nodular hyper¬ 
plasia, and hepato cellular carcinoma. Klatskin in his review 
(14) concludes, however, that the evidence implicating oral contracep¬ 
tives in the pathogenesis of liver tumors must be regarded as 
circumstantial rather than conclusive. Oral contraceptives may 
also induce hepatobiliary dysfunction. Increased sulfabrom- 
ophtalein retention and a few cases of jaundice have been re¬ 
ported (7). Two prospective studies, the one in 1974 by the 
RCGP and one by Howat et al., have established a link between 
oral contraceptive use and gall bladder disease. These are 
reviewed in McQueen (7). Bennion et al. in 1976 reported that 
use of oral contraceptives increases cholesterol saturation in 
gall bladder bile as well as changing the relative proportions 
of various bile acids in the bile (15). 
Liver tumors aside, oral contraceptive use may be associ¬ 
ated with a variety of other forms of neoplasia. Endometrial 
carcinoma has been associated with sequential oral contracep¬ 
tives. This association plus data demonstrating they were less 
effective caused the removal of sequential oral contraceptives 
from the U.S. market in 1976. The RCGP study, 1974, showed 
no association between breast cancer and use of oral contra¬ 
ceptives in human users. However, data implicating megestrol as a 
causative agent of increased breast neoplasia in beagle bitches caused 
7 
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the removal of all megestro1-conta ining oral contraceptives from 
the U.S. market in 1975. In 1978 medroxyprogesterone (Depo- 
Provera) was withdrawn from the U.S. market. One of the reasons 
cited by the FDA was that safety questions, raised by studies in 
dogs showing an increase in mammary tumors associated with the 
drug,had not been resolved (16). Use of oral contraceptives may 
increase risk of relapse from trophoblastic tumors. There is 
little data in this area; one study is reviewed in McQueen (7). 
Finally it was thought that oral contraceptives might increase 
the rate of cancer of the cervix on the basis of a study by 
Melamed, Koss, Flehinger, Kelisky, and Dubrow comparing women 
using oral contraceptives and women using diaphragms. This 
conclusion has been questioned on grounds of methodological 
problems in the study. These are reviewed by Andrews (8). 
Progestogens administered as pregnancy tests may increase 
the incidence of congenital anomalies. Data from the Drug 
Epidemiology Unit, Boston University Medical Center, the Harvard 
School of Public Health, and the New York State Birth Defects 
Institute indicates an association between in utero exposure 
to female hormones and cardiovascular birth defects as re¬ 
viewed in McQueen (7). Aarskog in 1977 reported, on the basis 
of several retrospective studies including his own, that 
maternal use of progestogens may cause hypospadias (17). In 
other papers vertebral, anal, cardiac, tracheal, esophageal, 
and limb reduction defects have been reported. 
Lastly, oral contraceptive users have been variously 
cited in the to suffer more frequently from urinary 
8 

tract infections, phoyosensitivity, erythema multiforme, ery¬ 
thema nodosum, porphyria, and acne (18). 
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Part B - Oral Progestational Agents: Possible Liver 
Mediated Side Effects 
Several reported effects of hormonal contraception 
reviewed above may be mediated by progesterone. Within this 
category there are four principal areas that may involve the 
liver—blood pressure, blood coagulation and fibrinolysis, 
carbohydrate, and lipid metabolism. The literature in each of 
these areas will now be briefly reviewed. 
The first report of increased blood pressure associated 
with oral contraceptive use occurred in 1962. Since that time 
there have been a number of studies on this topic dealing with 
the role of progestogens. In 1972 Spellacy and Birk reported 
on a controlled prospective study involving 415 normotensive 
women (19). Three types of progestogen were investigated as 
single contraceptive agents--medroxy-progesterone acetate, 
norgestrel, and ethynodio1 diacetate. The authors found that 
diastolic blood pressure was lowered with the norgestrel and elev¬ 
ated with medroxy-progesterone acetate. There were no signi¬ 
ficant changes in systolic pressures. Apart from finding that 
the type of steroid ingested was important, the investigators 
also found that the type of subject ingesting the steroid 
affects the results (e.g. previous pregnancy hypertension 
vs. normal pregnancy). In 1974 Weir et al. (20) found an 
association between rise in blood pressure and progestogen 
dose. This conclusion was based on a study of 134 Scottish 
women after two years therapy with combination-type oral contra¬ 
ceptives containing similar estrogenic dose (50yg of mestranol 
10 

or ethinyl estradiol), but varying progestogen doses (1.0 
mg of norethisterone, 2.5 mg of lynestrenol, 3.0 mg of noreth- 
isterone, or 4.0 mg of megestrol). This conclusion may be subject 
to doubt on the basis of methodological problems arising from 
dealing with the differing potencies of the compounds employed. 
Edgren and Sturtevant (21) point out that there are mutual 
interactions between the estrogenic and progestational compo¬ 
nents of combined pills. Furthermore, mestranol and ethinyl 
estradiol are not of equivalent estrogenic potency. Varying the 
estrogen/progestogen ratio in the above formulations may have 
effects on the progestogenic effect that can not solely be ex¬ 
plained in terms of the varying dose of progestogen. 
In 1976 Laragh conducted a review of oral contraceptive 
induced hypertension (22). He postulates a mechanism for ster¬ 
oid hormone causation of hypertension involving both volume 
components mediated by the sodium-retain- and 
ing effects of estrogen in the presence of a relatively higher 
plasma renin activity, the latter being held abnormal by a 
high plasma renin-substrate level. Laragh conducted a study 
which showed that norethynodre1, a synthetic steroid with 
largely progestogenic activity, when administered alone, pro¬ 
duced significant but small increases in renin substrate levels 
with corresponding associated increases in plasma renin activ¬ 
ity. Ethinyl estradiol produced similar but quantitatively more 
striking effects. These data suggested to him that the estro¬ 
genic component is the major causative factor in the observed 
changes of the renin angiotensin-aldosterone system. 
11 
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Figure 1. The renin-angiotensin-aldosterone (RAA) system. 
Presented here is the vasoconstriction-volume hypothesis 
according to Laragh (ref. 22, p 143) . 
In 1977, Meade and association (23) reported on a pro¬ 
spective study involving 321 women on estrogen-progest in 
contraceptive pills containing either 30 yg ethinyl estradiol 
or 50 yg of either ethinyl estradiol or mestranol in combina¬ 
tion either with 150 or 250 yg norgestrel for the 30 yg 
estrogen pills or 1, 3, or 4 mg of norethisterone for the 
50 yg estrogen pills. They found that among women on 50 yg 
estrogen preparations, systolic blood pressure values in those 
taking 3 mg or 4 mg norethisterone were all higher than in those 
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taking only 1 mg. This difference they found to be statisti¬ 
cally significant, however they did not control for the varying 
potencies of the estrogens being used, ethinyl estradiol being 
about twice as potent as mestranol (21). Among the users of 
the 30 y g estrogen preparations, they found higher systolic and 
diastolic blood pressure values at the lower, 150 yg, dose 
of d-norgestrel than at the higher, 250 yg, dose of d-norgestre1 . 
The statistical significance was not stated here. These observa¬ 
tions were based on single blood pressure measurements without 
any pretreatment readings. 
Also in 1977, a report on the RCGP study (24) appeared 
detailing the effect on hypertension of the progestogen compo¬ 
nent of the pill in combined oral contraceptives. The authors isolated 
out of their study data a group of women taking combined oral 
contraceptives with 50 yg ethinyl estradiol in combination with 
varying doses of norethisterone acetate — 1,3, or 4 mg. During 
the course of the study, they found a statistically significant 
linear trend rate between dose of norethisterone acetate and 
number of first diagnoses of hypertension in women with no 
previous history of the condition. 
Most recently, Hall et al. (25) reported on a prospective 
study of the effect of oral progestational agents on blood 
pressure in 119 black, initially normotensive, women. Blood 
pressure was measured before inception of treatment and during 
the course of treatment. All women received .35 mg norethi- 
sterone (minipill). New minipill users were excluded if they had 
converted to oral progestational agents from other hormonal 
methods. Only women under age 35 and not currently using anti- 
13 
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hypertensive agents were included. The control was a group of 
673 black women matched to the same criteria who used non- 
hormonal contraceptive methods during the study period. Data 
consisted of blood pressure changes after at least 6 months and 
up to 24 months of treatment, minipill or nonhormonal forms 
of contraception. The authors found, "no evidence of association 
between oral progestational contraceptive therapy (.35 mg of 
norethisterone) and the development of elevated blood pressure 
in black women below age 35 remaining on minipill therapy for 
approximately 1 year." 
Since the late 1960's there have been numerous reports 
dealing with the effect of oral contraceptives on the coagulation 
system. A number of these have dealt with the role of progesta- 
genic agents in affecting the clotting system and the risk of 
thromboembolism. In 1970 Inman et al. (26) reported on a large 
retrospective study of thromboembolic disease and the steroidal 
content of oral contraceptives. They found a positive correla¬ 
tion in the United Kingdom between the dose of estrogen and the 
risk of pulmonary embolism, deep vein thrombosis, cerebral throm¬ 
bosis, and coronary thrombosis. They also found a similar assoc¬ 
iation for venous thrombosis and pulmonary embolism in Sweden 
and Denmark. No significant differences were detectable between 
sequential and combined preparations containing the same doses 
of estrogen, nor between the two estrogens, ethinyl estradiol 
and mestranol. With respect to the progestagenic component, 
the authors found that the combination of 100 yg of mestranol 
14 
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with 2.5 mg of norethynodrel was associated with a significant 
deficit of reports of thromboembolic disease compared with the 
other combinations, mestranol 100 yg plus norethisterone 2 mg, 
amd mestranol 100 yg plus ethynodrel diacetate 1 mg. They also 
found that the combination of 50 yg of ethinyl estradiol with 
4 mg of megestrol acetate showed a significant excess of reports 
of only venous thromboembolism (not cerebral or coronary) in 
comparison with other combinations of progestogen with the same 
dose of ethinyl estradiol. These latter were ethinyl estradiol 
50 yg combined with 4 different doses of norethisterone 
acetate: 4 mg, 3 mg, 2.5 mg, and 1 mg. These comparisons 
suggest it is not only the estrogens that are related to the 
risk of thromboembolism. 
Also in 1970, Howie et al. (27) reported that progestin 
therapy had no significant effect on coagulation or fibrinoly¬ 
sis, whereas estrogen and combined estrogen-progestin therapy 
increased plasma antiplasmin and decreased serum anti-thrombin 
activity. The combined estrogen-progestin preparation used 
contained 50 yg mestranol and 1 mg ethynodiol diacetate. The 
progestin preparation used was ethynodiol diacetate (1 mg). 
This clinical study was based on a sample of 29 women divided 
into four groups. The experimental groups received the steroids 
for the period of one menstrual cycle. 
In 1971 Poller et al. reported a study on blood clotting 
and platelet aggregation during progestogen contraception with 
chiormadinone acetate (28). They found in their clinical study 
no increase in the level of factors VII and X as had been found 
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with estrogen-progestogen combined oral contraceptives. They 
further found that clotting factors that had been raised when 
the women were taking combined preparations became normal 
after 6 monthly cycles of progestogen use alone. In a related 
study reported in 1972 (29) Poller et al. studied the effects 
of norethisterone on blood clotting and platelet parameters. 
This was a clinical study of 63 women divided into 4 test groups. 
In the group that had not previously taken oral contraceptives, 
no acceleration of clotting or platelet factors was found when 
they started norethisterone contraception. In contrast a tendency 
to reduced coagulability was found. The group of women who had 
previously taken combined estrogen-progestogen preparations 
showed reduced clotting and platelet parameters when switched 
to norethisterone. Finally, no changes in clotting or platelets 
were found in women who changed to norethisterone from the 
1 7-acetoxysteroid progestogen ch1ormadinone acetate or in the 
group of women who started on norethisterone postpartum. 
Also in 1972 Mink and association (30) reported on a double 
blind study involving 35 women on either a progestin, combined 
progestin-estrogen therapy, or no medication (contraception via 
intrauterine device). The progestin treatment employed was a 
daily .5 mg dose of ch1ormadinone acetate. The progestin- 
estrogen combination therapy consisted of 21 days of 1 mg noreth- 
indrone acetate plus .05 mg mestranol followed by 7 days of a 
placebo tablet. The authors found in the progestin-estrogen 
(or P & E) group highly significant changes toward hypercoagula¬ 
bility at 3 months in Quick time, Factor II, Factor VII, and 
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Factor X. Significant increases in activity or level also were 
apparent in the TGT screen, thromboe1 astogram clotting time 
rrk, Factor V, Factor IX, and plasminogen. In the progestin 
(or P) group, there were found barely significant changes toward 
hypercoagulability at 3 months in Quick time and Factor VIII. 
There also was quite a significant increase in Factor IX and a 
highly significant decrease in Factor X. In the C, or control, 
group there was noted a statistically significant increase only 
in activity in the TGT screen between 3 and 6 months. The 
authors note that in the P group the change in Quick time activi¬ 
ty was not nearly as marked as that which occurred in the P&E 
group. Further, they note that Factor IX, involved in the in¬ 
trinsic generation of thromboplastin, rose during both chlor- 
madinone and combination therapy, suggesting a progestogen- 
induced phenomenon. 
In the more recent literature, Ambrus (31) et al. re¬ 
ported a summary of 4 separate studies that had been conducted 
over a ten year period relating oral contraceptives to changes 
m hematologic parameters. They found that, "oral contra¬ 
ceptives increase circulating blood levels of several pro¬ 
coagulants and fibrinolytic system components and that these 
effects are related primarily to the estrogen portion of the 
oral contraceptives." (p. 1057) In their trials 1, 2, and 3, 
decreasing doses of a synthetic progestational agent (norethin- 
drone acetate) were used in combination with a standard amount 
of a synthetic estrogen (ethinyl estradiol). In trial 4, dis¬ 
cussed earlier (30), a progestin (ch1ormadinone acetate) given 
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alone was compared with a norethindrone-mestrano1 sequential 
combination. A total of 348 women (262 treated and 86 control) 
were studied. 
Lastly, in 1978, Korsan-Bengsten and Larsson (32) re¬ 
ported their clinical study of blood coagulation and fibrinoly¬ 
sis in 13 women using steroid hormone contraception.In this 
study, the contraceptives used were a pill containing 50 yg 
ethinyl estradiol combined with .5 mg quingestiano1 given in 
3 week periods and a pill containing only norethisterone at a 
dose of .3 mg and given daily without interruption. The 13 
women in the study served as their own controls. Observed were 
a significantly increased fibrinolytic activity and a signi¬ 
ficantly increased variation in plasminogen in the women on 
the combined contraceptives. These changes were not observed 
in the women on norethisterone alone. Other blood coagulation 
parameters were not significantly changed by either regimen. 
The authors note, though these results implicate estrogen as 
the major causant of ora 1-contraceptive-associated changes in 
coagulation and fibrinolysis, that the number of patients in 
the study is not large enough to warrant any definite conclusion. 
18 

The third major area among progestogen associated contraceptive side 
effects with possible liver mediation is carbohydrate metabolism. This is 
well reviewed in Spellacy (33), Kalkholf (34), and Beck (35). The effect 
of chronic ingestion of contraceptive steroids appears to be related to the 
age and predisposition to metabolic disease of the recipient and to the 
amounts and relative proportions of estrogen, nortestosterone, and 
progesterone derivatives in the birth control preparations employed. 
The estrogenic components of combined or sequential agents are synthetic 
modifications of estradiol and take the form of mestranol (3-methoxyethiny- 
estradiol) or ethinyl/estradiol. The progestin ingredients may be related to 
19-nortestosterone (e.g. norethindrone, norethynodrel, norethisterone) or 
they may be related to esterified 17a-hydroxyprogesterone (e.g. acetates 
of chlormadinone, megestrol, or medroxyprogesterone). 
In women, according to Beck (35), the separate administration of 
contraceptive doses of either synthetic estrogens or progesterone derivatives 
or nortestosterone derivatives does not consistently alter glucose or 
insulin metabolism as assessed by serum glucose or insulin concentrations 
after overnight fasting or following glucose administration. However, 
Spellacy e_t aJ. (36), in a paper appearing too late for Beck’s review, found that 
norethindrone does exert a carbohydrate metabolic effect. This study was 
based on 3-hour oral glucose tolerance tests performed on 53 women before 
and after 6 months of continuous daily oral therapy with .35 mg of 
norethindrone. Spellacy and co-workers found a significant increase in the 
blood glucose and plasma insulin levels of these women after treatment. These 
changes in carbohydrate metabolism were significantly correlated with women 
of older age, higher parity, or those who gained excessively in weight during 
therapy. Jn a similar study with megestrol acetate, Spellacy _et al. (37) 
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developed data that suggested that the substituted progesterone 
progestins in oral contraceptives exert little metabolic effect as 
compared to the 19-nortestosterone-type progestins. 
A number of animal studies have been conducted involving synthetic 
progestins. These suggest the presence of metabolic effects. In Rhesus 
monkeys, administration of synthetic progestins alone, at doses higher 
than those comparable to conventional oral agents, causes an increase in 
plasma insulin response (34) . Weikel e_t a^. (38) conducted a study of 
the effect of chronic administration of megestrol acetate and chlormadinone 
acetate in female beagle dogs. Megestrol was administered orally for 4 
years at doses of .01, .1, or .25 mg/kg/day. Chlormadinone acetate was 
given in a dose of .25 mg/kg/day. At 4 years evidence of diabetes 
consisting of bilateral cataracts, elevated serum glucose concentrations, 
and glycosuria was noted for 2 of the 16 high-dose megestrol acetate and 
6 of the 15 chlormadinone acetate-treated dogs. 
The concurrent administration of mestranol or ethinyl estradiol with 
a nortestosterone derivative produces deterioration of glucose tolerance. 
This is not observed during concurrent synthetic estrogen-progesterone 
derivative administration (35). Goldman (39) studied the effects of Enovid, 
a combination-type oral contraceptive containing norethynodrel and mestranol. 
Women who took this combination for 12 months demonstrated a significant 
elevation of mean blood glucose levels in the fasting state. After Enovid 
therapy the women demonstrated elevated blood glucose and insulin levels 
during the intravenous glucose tolerance test. 
The mechanism by which oral contraceptives affect carbohydrate 
metabolism is not known: however, involvement of the liver appears likely. 
The liver is involved in carbohydrate metabolism, storage of glycogen 
and release of glucose. The liver is also involved in metabolism of 
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steroids. Many studies have demonstrated an alteration in liver function 
in women taking oral contraceptives. This observation is based on tests 
such as BSP excretion, liver biopsy, and routine liver function tests. 
It has been reported that fasting blood pyruvate levels may be elevated in 
some women on oral contraceptives. Blood triglyceride levels are 
elevated by oral contraceptive administration. Changes such as the above 
may reflect abnormal liver metabolism (33). 
The fourth and final major area among potential progestin associated 
side effects with liver mediation is that of lipid metabolism. A 
consistent pattern of change in serum triglyceride and cholesterol 
concentrations has been difficult to detect in women using birth control 
pills (35). Studies dealing with the effect of progestins on triglyceride 
metabolism have been reviewed in Beck (35,40). Reports have suggested 
tnat ethinyl estradiol and mestranol may cause increases in fasting 
plasma triglyceride and very low density lipoprotein (VLDL) concentrations. 
However no increase in circulating triglycerides has been observed after 
treatment with progesterone or synthetic progestins. No increase in 
fasting plasma or serum triglyceride concentrations has been observed in 
women treated with 17a-acetoxy progesterone derivatives. Spellacy and 
associates ( 37) studied the effects of 6 months of daily treatment with 
.5 mg megestrol acetate on a group of 42 women. No significant changes 
were found in triglyceride values. 
Treatment with 19-nortestosterone derivatives generally results in 
lower fasting serum triglyceride values. Among other studies on 
19-nortestosterone derivatives, Spellacy and co-workers (36), have reported 
on the effects of norethindrone on triglyceride concentrations. In their 
prospective analysis of the effect of 6 months daily treatment of .35 mg 
of norethindrone on 53 women, this group found significantly decreased 
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levels of fasting plasma triglycerides. However, other investigators 
have found no significant alterations in fasting serum triglyceride 
concentrations in normal subjects treated with either norethindrone 
acetate 5 mg/day or norethindrone .4 mg/day (35). 
In some studies, combined birth control pills have been found to 
cause elevations in circulating triglyceride levels. Combined pills 
containing nortestosterone derivatives have generally been found to 
cause lesser elevations than those containing progesterone derivatives. 
Data have been presented (35) that show that the hypertriglyceridemic 
effects of mestranol and ethinyl estradiol are dose-related. Increasing 
doses of norethindrone acetate may increasingly counteract the hypertrigly¬ 
ceridemic effect of a single dose of synthetic estrogen. 
The mechanism by which synthetic progestins lower fasting serum 
triglyceride levels is unclear, however it is apparent that the liver, as 
a seat of triglyceride metabolism, may be involved. Workers have reported 
that treatment with progesterone or megestrol leads to a decrease in 
serum triglyceride pool size and apparent clearance rate, without change 
in turnover rate, resulting thus in lower serum triglyceride concentrations 
(40) • 
The mechanism by which contraceptive steroids when in combined pills 
increase serum triglyceride concentrations is also unclear. Beck 
reports (35) that it has been demonstrated that triglyceride turnover 
and removal rates are accelerated in women using nortestosterone plus 
mestranol or ethinyl estradiol. Increased serum triglyceride concentrations 
may thus be due to a rate of triglyceride synthesis which exceeds removal 
rate. Beck (35) reports also on the work of others showing that the 
increase in serum triglyceride concentrations observed in women using 
contraceptive steroids appears predominantly in the low density lipoprotein 
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(LDL) fraction. This fraction is converted by extrahepatic parenchymal 
cells and scavenger cells to HDL (41)- The LDL fraction is also converted 
in the liver to VLDL. 
The area of contraceptive effects on cholesterol metabolism is also 
reviewed by Beck (35). According to Beck, available evidence suggests 
that contraceptive steroids alter serum cholesterol only a small amount. 
Increases in fasting serum cholesterol concentrations observed in birth 
control users are modest in comparison with the changes observed in 
fasting serum triglyceride concentrations in women on combined pills. 
Plasma cholesterol levels were unchanged or lowered in oophorectomized 
women treated singly with either ethinyl estradiol or low-dose mestranol. 
Low-dose chlormadinone acetate and norethindrone acetate administered 
alone do not substantially change circulating cholesterol levels. However, 
at a constant dose (50 yg/day) of estrogen, increasing doses of 
norethindrone are associated with increasing fasting serum cholesterol 
concentrations. 
Appearing in the literature since Becks' review, Bradley et^ al. (42) 
have reported on their study of serum high-density-lipoprotein cholesterol 
in women using oral contraceptives. In a cross-sectional study, 
Bradley and co-workers analyzed the serum levels of high-density-lipoprotein 
cholesterol in 4978 women 21 to 62 years of age. They found that in 
estrogen users the mean level of this lipid was 6.7 to 15.1 mg per deciliter 
above the nonuser level whereas in a group of progestin users it was 15.8 mg 
per deciliter below the nonuser level. Both of these differences were 
highly significant. The estrogen users studied included groups on 
a) conjugated or esterified estrogen dose _< .625 mg, b) conjugated or 
esterified estrogen dose 1.25 mg, c) ethinyl estradiol dose, .02 mg 
and, d) ethinyl estradiol dose .05 mg. The progestin users studied were 
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a group on norethindrone acetate, dose 5.0 mg. Bradley and co-workers 
found that users of combinations of estrogens and progestins show values 
of high-density-lipoprotein cholesterol intermediate between those of 
users of estrogens alone and those of women taking progestins alone. 
They further found that the effect of progestin appears to be opposite 
to that of estrogen when a combined preparation is used. In two groups 
on combined pills containing the same dose of ethinyl estradiol (.05 mg) 
the concentration of high-density-lipoprotein cholesterol dropped in a 
statistically significant fashion apparently in association with a rise 
in dose of norethindrone acetate from 1 to 2.5 mg. 
The authors state that their findings are consistent with the known 
estrogenic and antiestrogenic activities of the various progestins. 
Norethynodrel, which has almost no antiestrogenic effect,was found to be 
associated with high concentrations of high-density-lipoprotein cholesterol. 
Norethindrone acetate and norgestrel both with strong anti estrogenic 
effects were associated with the lowest levels. The authors conclude 
however that because the data are cross-sectional and not prospective 
direct causal relations cannot be logically inferred. 
The mechanisms by which contraceptive steroids alter cholesterol 
metabolism are not certain. They appear related to age and ovarian function 
according to Beck (35). Beck also notes that examination of circulating 
lipoprotein patterns does not provide a clue to the mechanisms involved. 
Ethinyl estradiol and conjugated estrogens in post menopausal women 
increase the cholesterol content of HDL’s but lower the cholesterol content 
of LDL’s. On the other hand, testosterone derivatives lower the HDL 
cholesterol content and increase LDL cholesterol content. Whatever the 
specific mechanism, it is quite likely that the liver is involved in some 
fashion. The liver is known to metabolize LDL particles and cholesterol 
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and it synthesizes VLDL particles. The cholesterol esters that are 
formed on the surface of HDL particles are transferred to VLDL and 
eventually appear in LDL particles (41). 
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Part C Progestin Receptors: General Properties and Distribution. 
It is currently believed that progestins behave in a manner similar 
to other steroid hormones. In the general scheme the steroid binds to 
a specific cytosol receptor protein and undergoes a temperature-dependent 
activation step. The hormone-receptor complex then is translocated to the 
nucleus whereupon it is bound to the target cell genome. RNA synthesis 
increases and specific mRNA’s are transcribed. Finally the mRNA’s are 
transported to the cytoplasm and the synthesis of hormone specific proteins 
is enhanced (43). 
To qualify as a receptor, a binding substance must fulfill these 
criteria: high affinity, finite binding capacity, hormone specificity, 
tissue specificity, and correlation with biological response. The 
general properties of progestin receptors are reviewed in JUnne e_t _al. (44). 
Characterization of progesterone receptors has turned out to be more 
difficult than that of estrogen and androgen receptors. According to 
Jclnne jBt aT. the obstacles in this work have included a lower affinity 
for the interaction between progesterone and its receptor than for 
that of other steroids and their receptors. Receptor-progesterone 
complexes are known to have a rapid rate of dissociation. Furthermore 
progesterone associates with corticosteroid binding globulin (CBG). 
A CBG-like protein has been found in the uteri of several mammalian 
species. These problems have been dealt with by the inclusion of 
glycerol in the buffers employed and by the use of special radioactive 
3 
synthetic progestins including H-R5020 (17,21-dimethl-19-nor-4,9- 
3 
pregnadiene-3,20-dione), H-ORG 2058 (16a-ethyl-21-hydroxy-19-nor-4- 
3 
pregnene-3,20-dione) and H-medroxyprogesterone acetate (MPA, 6a-methyl- 
17a-hydroxy-4-pregnene-3,20-dione acetate). These synthetic progestins 
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dissociate at a slower rate from the receptor than progesterone. They 
also do not associate with CBG to a significant degree (44). 
Progesterone receptors have been identified in a number of 
tissues in experimental animals and in humans. This subject is reviewed 
by Leavitt et al. (45). Distinct progesterone-binding components have 
been described in endometrium and myometrium. In hamster, guinea pig, 
and sheep the physiochemical properties of endometrial and myometrial 
receptors appear to be identical on the basis of sedimentation 
coefficient, binding affinity, and ligand specificity. Experimental 
results indicate the presence of an estrogen-inducible progesterone 
receptor in the cytosol fraction of deciduomal tissue in pseudopregnant 
hamster. A specific progesterone binder, similar to the uterine progesterone 
receptor has been identified in vaginal cytosol from the guinea pig and 
hamster. O’Malley and his group have identified progesterone receptor 
in the chick oviduct (43) . A putative progesterone receptor has also been 
identified in hamster pituitary and hypothalamus. Finally, specific 
progesterone receptors have been detected in mouse mammary tissue. In 
the rat alone cytosol progesterone receptors have been identified in 
uterus (46), ovary (47), pituitary, hypothalamus, cortex (48), preoptic 
area,agmygdala, mid brain (49), and isolated islets of Langerhans (50). 
In the human subject, cytosol progesterone receptors have been 
identified in uterine myometrium and myoma (51)5 uterine endometrium (52), 
and breast cancer (53). 
According to JMnne (44) studies of binding properties of progestin 
receptors in human, sheep, rabbit, and guinea pig uterus have revealed 
marked species differences in these receptors. Sheep and rabbit myometrial 
receptors possess binding properties very similar to those of human 
receptors. However, guinea pig receptor appears to differ in that it binds 
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poorly two groups of steroids (pregnane derivatives with substitutions 
in the D-ring and the 17a-ethiny1-176-hydroxy estranes) that were 
tightly bound by the human, rabbit, and sheep receptors. The steroids 
of the two groups above also are poorly bound by the chick oviduct 
progestin receptor. Thus the nature of progestin binding sites may 
not be identical in all species. 
In the past few years it has become apparent that progesterone 
receptor levels are regulated by estrogen and progesterone. This area 
is reviewed by Leavitt e_t al_. (45) and JHnne e_t al. (44)- In guinea 
pig, hamster, and rat uterus fluctuations in cytosol progestin receptor 
level follow the same patterns during the estrus cycle. There is a peak 
at proestrus which is followed by a decline at estrus and metestrus. 
At diestrus there is a new increase. In human endometrium and myometrium 
cytosol.progestin receptor has higher levels during the follicular 
phase than luteal phase of the menstrual cycle. 
The results above are consistent with the findings of studies where 
exogenous estrogens and progestins have been administered. Moguilewsky 
and Raynaud (48) found that in both immature and castrated adult rats, 
estrogen (moxestrol) administration increased the number of R5020-specific 
binding sites in the uterus, pituitary, and hypothalamus. Kreitman and 
co-workers (52) studied the concentration of progesterone receptors,both 
cytosol and nuclear, in the endometrium of 14 post menopausal patients. 
They found that ethinylestradiol increased progesterone receptor 
concentration in a statistically significant fashion. They further found 
that chlormadinone acetate prevented this increase. As a result of these 
and other studies, workers in this area have been led to conclude that 
estrogens promote the synthesis of new progesterone receptors. Furthermore, 
progesterone and other progestins seem to exert a depressive effect on 
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cytosol progesterone receptor content (44). 
To this point in time the presence of progesterone receptors has not 
been demonstrated in normal liver tissue. MacDonald and co-workers (54) 
have reported that hepatic adenoma may have estrogen and progesterone 
binders. Studies, reviewed by Stumpf and Sar (55), of the uptake of 
3 
[ H] progesterone after injection have demonstrated nuclear labelling in 
rat and guinea pig uterine tissues. In guinea pig, pretreatment with 
progesterone reduces the nuclear concentration of radioactivity in 
oviduct, uterus, cervix, and vagina. In guinea pig liver radioactivity 
is distributed in cytoplasm of hepatocytes. Certain hepatocytes stand 
out in concentrating very high amounts of radioactivity in their cytoplasm. 
In the liver as opposed to the other organs studied,the radioactivity 
seen within a cell is associated not with progesterone but with metabolites 
of progesterone. 
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MATERIALS AND METHODS 
Part A - General Protocols 
1. Animals and Materials 
Female rats were obtained from Charles River (CD strain) 
and Camm (Sprague Dawley). At sacrifice, the intact females 
were post-pubescent by weight (220-280 g) and age (10 to 17 
weeks). The rats were anesthetized with ether and perfused 
with 20 ml normal saline through the left ventricle after in¬ 
cising the right atrium. The livers and, in some experiments, 
the uteri were then quickly excised and retained on ice. 
3 
H-R5020 (Promestone=17,21-dimethyl-19-nor-pregna-4j 9-diene- 
3,20-dione at 87 Ci/mmol) was obtained from New England Nuclear, 
Boston, MA. Before each experiment, a portion of the tritiated 
R5020 stock was evaporated to dryness under nitrogen and re¬ 
dissolved in absolute ethanol to give the required concentration. 
Radioactivity was determined in a Packard 3380 liquid scinti- 
lation spectrometer at 39 percent efficiency to assure accurate 
concentrations to within 10 percent. 
All nonradioactive steroids were of highest purity 
available from commercial sources. Nonradioactive stock so¬ 
lutions of R5020 , progesterone, R1881 (me thy 11rieno1one = 
17B-hydroxy-17a-methy1-estra-4,9,11-trien-3-one), and cortisol 
were made fresh from the powders dissolved into absolute ethanol. 
Ethinyl estradiol for injection was dissolved in propylene 
glycol . 
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2. Cytosol Preparation 
All subsequent steps were performed at 0-4°C unless 
otherwise stated. The livers and, in some experiments, uteri 
were weighed, minced, and homogenized in 6 vol (wt/vol) of 
Progesterone Assay Buffer (.005 M Na^HPO^ 10% glycerol, by vol, 
.001 M dithioglycerol @pH 7.4) (56) using teflon homogenizers 
for liver and conical glass homogenizers for uterus. The liver 
homogenates were centifuged at 25,000 x g for 10 minutes. 
The supernatants of the above centrifugations were then cen¬ 
trifuged at 105,000 xg for 60 minutes and the clear super¬ 
natants retained as the cytosol fractions. The protein con¬ 
centrations of the cytosols ranged between 10-14 mg/ml for liver 
and 5-7 mg/ml for uterus. 
3. Ammonium Sulfate Precipitation 
A neutralized saturated ammonium sulfate solution was 
added to the liver cytosols to the required final concentration; 
30%, 40%, 50%, 60% (vol/vol) depending on the experiment. The 
suspensions were stirred for 45 min on ice and then centrifuged 
at 23,000 x g for 10 min. The supernatants were discarded, and 
the precipitates were redissolved in progesterone assay buffer 
to the required fraction of original cytosal volume; 1/6, 1/5, 
1/4 and 1/2.2 depending on the experiment. These resuspensions 
would yield, respectively, 6, 5, 4, and 2.2-fold concentrations 
of the ammonium sulfate preparation. 
4. Binding Assays and Thin Layer Chromatography 
Unless otherwise stated, 200yl portions of the ammonium 
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sulfate preparation were transferred to assay tubes. To examine 
competition with nonradioactive steroids, the competitors 
3 (dissolved in 2 yl ethanol) were added before the H-R5020. 
The binding assays (dome in triplicate unless otherwise stated) 
3 
were commenced by the addition of the H-R5020 and vortexing. 
The samples were incubated in ice for 1 hour. 
Afterwards,the macromo1ecu1 ar bound radioactivity was deter¬ 
mined using small polyacrylamide gel filtration columns (Biogel 
P10; 20,000 exclusion mol wt; 1.1 x 10 cm) maintained in a 4°C 
cold room. Tris-HCl (0.01 M, pH 7.4) was used for column 
equilibration and sample elution. Blue Dextran (1% in 1OmM 
Tris-HCl buffer) was added in .1 ml aliquots to each sample. 
Samples cum dextran marker were carefully layered on to the 
columns and washed with 1 ml 1OmM Tris KCl buffer.The columns were 
eluted with the Tris buffer and 3 ml samples were collected 
containing the macromo1ecu1 ar bound fraction as marked by the 
dextran. Non-polar radioactivity was extracted from the samples 
by adding 10 mis of a toluene: isoamyl alcohol (19:1) 
mixture and shaking for 20 minutes. Then 3 ml aliquots of the 
non-aqueous phase were removed, placed in minivials, and mixed 
with .5 ml each liquifluor. This cocktail, yielding 39% 
efficiency, was counted in a Packard 3380 liquid scintillation 
spectrometer. 
The identity of the radioactivity in the incubation mixtures 
was determined for experimental groups 2,3, and 5 (see specific 
experimental protocols for description of groups) using thin 
layer chromatography. Samples for chromatography were derived 
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3 
from tubes set up for incubation at 20nm H-R5020 without compe 
titor. These were not run on gel filtration columns. Extraction 
was as for the other samples. This was followed by centrifugation 
for 10 min at setting #35 (IEC Model K centrifuge, rotor=250) and 
careful removal of the toluene-is oamy1 alcohol phase. One half ml 
of this extract was dried down for experimental group 3 and one 
ml of extract for experimental groups 2 and 5 to yield samples 
for spotting with 4,000-6,000 CPM per 5 yl. These were run in 
parallel lanes to a H-R5020 standard, unmetabolized, made up fresh 
from the (87 Ci/mmol) stock and containing 7,000 cpm per 5 pi. 
The chromatography system consisted of Kodak 13181 silica gel with 
fluorescent indicator (no. 6060) and an elution solvent of 70% 
benzene-30% ethyl acetate. Once the chromatography runs were comple¬ 
ted, the solvent fronts were marked, the sheets dried, and any 
spots outlined under ultraviolet light (Chromato-vue hood, San 
Gabrie1,CA.). The sheets were then cut into squares, each one 
being placed in a scintillation vial with one ml absolute ethanol, 
shaken for ten minutes, and counted at 37% efficiency. 
In experimental group 4 (containing only one experiment) 
the identity of the radioactivity determined was that in the macro- 
molecular bound fraction. Here the samples for radioactivity were 
derived from the uncounted portion of the to 1 uene-isoamy1 alcohol 
phase from the experimental tubes. The experimental tubes were 
spun for 10 min at setting #35 (IEC, Model K centrifuge, rotor= 
250) and 4.5 mis of to1uene-isoamy1 alcohol phase was removed from 
each. This was pooled into two fractions, 32 mis each, according 
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to the tube of origin: a) that from the tubes incubated without 
competitor, and b) that from the tubes incubated in the presence of 
lOOOnM R5020. These were counted at 37% efficiency with results 
of 2390 cpm for fraction a) and 1380 cpm for fraction b). The two 
fractions were then flash evaporated, brought up in lOyl of abso¬ 
lute methanol, then recounted (37% efficiency) with results of 
1004 cpm for fraction a) and 843 cpm for fraction b). Losses 
occurred due to a pipetting error and use of sample for check 
counts. Samples a) and b) were then run on TLC sheets and counted. 
5. Protein Determination 
The concentration of soluble protein in the raw and in the 
ammonium sulfate purified cytosol fractions was determined accord¬ 
ing to the method of Lowry et al. (57) using bovine serum albumin 
(Worthington) as standard. These values were used to calculate the 
3 . . 
amount of macromo1ecu1 ar bound H-R5020 per milligram protein. 
6. Data Ana lysis 
For each data point (triplicate unless otherwise indicated), 
the mean and standard error of the mean (SEM) were calculated. 
The SEM's are presented in all charts. In comparisons between tubes 
with and without competitor Student's t test was employed to 
determine statistical significance. 
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Part B - Specific Experimental Protocols 
3 
1. a) Macromolecular Binding of H-R5020 in Rat Liver 
Cytosol Preparation with and without Ammonium Sulfate 
Purification. 
3 
b) Macromolecular Binding of H-R5020 in Rat Uterine 
Cytosol Preparation without Ammonium Sulfate Puri¬ 
fication. 
Livers and uteri were removed from two adult intact virgin 
female rats (Camm) and cytosols were prepared as above. The liver 
cytosol from one rat was purified using a 30% ammonium sulfate 
(AS) precipitation and concentrated 6-fold. This was divided into 
3 
two portions. One was incubated at 4 nM H-R5020 with a) no cold com¬ 
petitor, b) 200 nM R5020, c) 200 nM progesterone, and d) 200 nM 
cortisol. The liver cytosol preparation from the remaining rat 
. . 3 
was incubated without purification at 4 nM H-R5020 in the absence 
of cold R5020, then in the presence of both 200 nM R5020 and 200 nM 
progesterone. 
The uterine cytosols from both rats were independently and 
without ammonium sulfate purification incubated at 4 nM R5020. One 
preparation was incubated without cold R5020, with 200 nM R5020, 
and with 200 nM progesterone. The other preparation was incubated 
without cold R5020, with 200 nM R5020, and with 200 nM cortisol. 
3 
2. a) Macromolecular Binding of H-R5020 in Rat Liver Cyto¬ 
sol Preparation with Incubation before Ammonium Sulfate 
Purification. 
Livers were removed from 3 adult intact virgin female rats 
(2 Camm, 1 Charles River) and cytosols were prepared as above. The 
cytosol preparations from two of these rats, 1 Camm and 1 Charles 
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River, were incubated at 20 nM H-R5020 under four conditions: no 
cold competitor, 1000 nM R5020, 1000 nM progesterone, and 1000 nM 
R1881. Incubation was carried out as outlined in the general pro¬ 
tocol except that the volume of each incubate was 3 ml, a 15 x 
increase. The two preparations were independently purified with a 
40% ammonium sulfate precipitation, each incubation condition 
being handled separately in duplicate for a total of 16 ammonium 
sulfate cuts. Lowry protein determinations were performed on the 
unpurified cytosol and, as a check for uniformity, on all 18 AS 
cuts. Macromo1ecu1 ar binding was then determined as above, with 
each AS cut being divided for running on 3 separate gel filtration 
columns. TLC was performed on samples from the 2 preparations 
above as indicated in the general protocol. 
In a separate experiment, the liver cytosol preparation from 
. . . 3 
the remaining Camm rat was incubated at 20 nM H-R5020 under the 
conditions of no competitor, 1000 nM R5020, and 1000 nM progesterone. 
Incubation was performed as described in the general protocol, 
except that the volume of each incubate again was 3 ml. Each of 
the above incubation conditions was separately and in duplicate 
subjected to a 30% ammonium sulfate cut with a 5-fold concentration. 
Lowry protein determinations were performed on each of the 6 AS 
cuts and on two aliquots of unpurified cytosol. Macromo1ecu1 ar 
binding was then determined with each cut being split for running 
on three columns. 
From the same Camm rat, a uterine cytosol preparation was 
obtained as above. This was incubated without purification as 
3 
described in the general protocol at 20 nM H-R5020 a) without 
R5020 and b)with 1000 nM R5020. A Lowry protein determination 
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was performed on this cytosol. 
During the latter experiment, a test for a possible micro¬ 
crystallization artifact was conducted. The concern was that in tubes 
3 
of H-R5020 incubated with cold R5020 microcrysta 1s might form 
and alter the concentration of ligand. Four incubation tubes were 
set up, each with .5 ml unpurified liver cytosol, 2 with 20 nM 
3 3 
H-R5020 only, and two with 20 n; H-R5020 plus 1000 nM cold R5020. 
These were allowed to incubate for 50 minutes. At the end of that per- 
3 
lod they were sampled, one tube with only H-R5020 near the top of 
3 
the incubation mixture, the other tube with only H-R5020 near the 
bottom; one tube with hot and cold R5020 near the top of the mix¬ 
ture, the other tube with hot and cold R5020 near the bottom. The 
samples were counted and found to fall within 6% of each other 
and within 15% of the counts expected on the basis of calculated 
3 ... 
H-R5020 concentrations. From this test it appeared that concentra- 
3 
tions of H-R5020 in incubation tubes did not vary appreciably 
with location in the incubation mixture or with the absence or 
presence of cold R5020. This was, however, not tested statistically. 
3 
3. Macromolecular Binding of H-R5020 in Purified Rat Liver 
Cytosol Preparation with Independent Ammonium Sulfate 
Cuts: 30%. 40%, 50%, 60%. 
Livers were removed from 2 adult intact virgin female rats 
(Charles River) and cytosol preparations were obtained as above. These 
were pooled, divided into four groups, and purified with 30,40, 
50, and 60% AS precipitations. The resultant preparations were 
concentrated 4-fold. Lowry protein determinations were performed on 
unpurified cytosol and also on a sample from each of the 4 concentrates. 
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The four groups were then further subdivided into 4 incubating 
conditions each. Thus incubation occurred at each level of AS 
precipitation under 4 conditions: no competitor, 1000 nM R5020, 
1000 nM progesterone, and 1000 nM cortisol. Macromo1ecu1 ar binding 
was determined as described previously. 
3 
4. Macromo1ecu1 ar Binding of H-R5020 in Isolated, Intact 
Liver Parenchymal Cells. 
Liver cells were prepared as outlined in (58) in cooperation 
with Dr. Ray Aten of the Yale Obstetrics and Gynecology Laboratory. 
An adult, intact virgin CD female (Charles River) was 40% urethane 
anesthetized, then injected with .1 ml heparin, shaved, sprayed, 
and prepared for perfusion. The vena cava was ligated above the 
right kidney, the right atrium was incised, and the liver was 
perfused with 300 ml Ca++/Mg++free Hanks' solution (Grand Island 
Biological Co., Grand Island, N.Y.), pH 7.4 at 37°C, at roughly 
15-20 mls/min. All perfusion solutions were continuously bubbled 
with 95% 0^-5% CO^. The liver was kept at 37° C by covering it 
with warm sa 1ine-soaked gauze and warming it with a high intensity 
lamp. Next, 100 mis of collagenase solution with Ca /Mg free 
Hanks' solution, 70 mg CaCl , 5 mg soybean trypsin inhibitor 
(Sigma Chemical Co., St. Louis, MO.), and 50 mg crude collagenase 
(Sigma) at 37° C, pH 7.4, was perfused through the liver at 15-20 
mls/min. This solution was recycled to a 37° C oxygenation cylinder 
via a cannula in the interior vena cava. As the perfusion neared 
completion, the flow rate was increased to maintain a constant 
vena cava outflow rate and to compensate for small leaks that 
developed in the liver as it began to be structurally digested by 
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the collagenase. After 15 minutes, the liver was carefully excised 
and placed in the collagenase solution also containing 1% bovine 
serum albumin (Ca 1biochem), in a petri dish. The outer membrane was 
removed, and the liver was gently disrupted for 3 min with scissors, 
forceps, and bubbling. Then, the liver was suspended in 100 ml of 
the same co 11 agenase-bovine serum albumin solution at 37° C and gently 
swirled and bubbled with 95% 0 - 5 % C0? for 10 min to release the 
individual cells. This suspension was filtered through nylon mesh, 
and the cells were allowed to sediment at room temperature for 5 
min in a 250 ml plastic beaker. A supernatant containing most of the 
nonparenchymal and trypan blue-staining cells was removed by 
aspiration. The cells, 6 g in a 12 ml volume, were resuspended 
at 37° C in 35 ml preoxygenated Waymuth's MB 752/1 medium con¬ 
taining 50 U penici11in/m1 and 50 pg streptomycin/m1 (Grand Island 
Biological). 
Two one-ml portions were taken for measuring the wet weight 
of the cells contained in 1 ml; roughly 175 mg. Thirty one-ml 
portions were then placed in 30 25-ml polycarbonate flasks which 
had been pre-warmed and O^-CO^ equilibrated. The cell suspensions 
were then preincubated for 10 min at 37° C under 95% 0^-5% CO^ 
in a Dubnoff shaker set at 60 rpm. After preincubation, 12 of the 
cell suspensions each containing 175 mg of cells in 3 mis of 
solution were placed on ice for 20 minutes. (The remaining 18 
suspensions were then used by Dr. Aten in an unrelated experiment.) 
3 
Incubation at 20 nM H-R5020 was performed as outlined in the 
general protocol, except that the volume of each incubate was 15 x 
larger. All flasks were incubated at 20 nM R5020 with six having 
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no cold competitor and six others having 1000 nM R5020. Upon comple¬ 
tion of incubation, the flasks were combined into 4 pools, 2 with 
no competitor and 2 with competitor. These 4 pools were first spun 
at 65 x g for 5 min (DAMON IEC centrifuge) and then washed two 
times, respun at 65 xg for 5 min (DAMON IEC centrifuge), aspirated, 
resuspended in Waymuth's medium. They were then spun again 65 * g 
for 5 min (DAMON IEC centrifuge) and resuspended in 6 vol (wet cell 
wt/vol) of progesterone assay buffer. The 4 pools were independently 
homogenized, u1tracentrifuged, and ammonium sulfate purified (40%, 
2.2:1) as indicated in the general protocol. Next they were each 
split in order to be run on 4 columns for a total of 16 samples. 
Macromo1ecu1 ar binding was determined as indicated in the general 
protocol. Lowry protein determinations were performed on each of the 
4 samples and on the unpurified cytosol. TLC was run as indicated 
in the general protocol. 
3 
5. Macromo1ecu1 ar Binding of H-R5020 m Independent 
Purified Cytosol Preparations of Liver from Two Rats 
Primed with Ethinyl Estradiol (EE^). 
Two intact virgin adult female rats (Charles River) were each 
injected with 100 mg of ethinyl estradiol (.1 ml of lmg/ml ethinyl 
estradiol in propylene glycol) every 24 hours for a 3-day period 
for a total of 300 mg ethinyl estrdiol. They were then sacrificed 
24 hours after the last injection. Liver cytosol preparations were 
. . . 3 
made from each, purified, and incubated at 20 nM H-R5020 with 
a) no competitor, b) 1000 nM R5020, c) 1000 nM progesterone, 
d) 1000 nM R1881, and e) 1000 nM cortisol. Macromo1ecu1 ar binding 
was then determined by gel filtration. Lowry protein assays were 
40 
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performed on samples of unpurified cytosol and purified cytosol 
from both of the preparations. TLC was performed to check for 
metabolism. All of the above was performed as indicated by the 
general protocol. 
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RESULTS 
A number of techniques are available to determine whether 
or not a progesterone-binding protein has the properties expected 
of a receptor. These include sucrose-g1ycero1 density gradient 
centrifugation for ascertaining sedimentation and general binding 
properties, the equilibrium assay for determining binding affinity 
(K ) and binding capacity, and the competitive binding assay for 
determining steroid binding specificity. The competitive binding 
assay was employed for the purposes of this investigation. 
Incubations were performed with a concentration of radioactive 
progestin ranging from around to several fold . This ensures 
that under the conditions of incubation most of the progestin- 
specific sites will be occupied by radioactive progestin. In the 
standard experimental run total, specific and nonspecific, binding 
of radioactive progestin is determined in an incubation with just 
cytosol and radioactive progestin. Nonspecific binding of radio¬ 
active progestin is determined in the incubation with cytosol, 
radioactive progestin, and competitor at a concentration 50x that 
of the radioactive progestin. The nonspecific sites are assumed 
to be of high capacity and low affinity. The specific sites, on 
the other hand, are assumed to be of high affinity and low capacity. 
Specific binding is then determined by the subtraction of 
nonspecific from total binding. 
The radioactive progestin used in this study is R5020 = 
17,21-dimethy1-19-nor-pregna-4,9-diene-3,20-dione. This was 
selected because it is resistant to degradation under i^n vitro 
conditions. It also does not bind with high affinity to plasma 
, i 
si 
proteins and is relatively specific for the progesterone receptor. 
R5020 forms a more stable, slow dissociating complex with the 
progestin receptor than progesterone itself (59). Aside from R5020, 
a number of other steroids were employed as competitors, 
progesterone, R1881(17g-hydroxy-17a-methyl-estra-4,9,ll-trien-3-one), 
and cortisol. If a progesterone-specific moiety is found in rat 
liver which is similar to progesterone receptors of uterus from 
estrogen-primed rabbits it may be ewpected to bind these steroids 
with the relative affinities, highest to lowest, R5020 230, R1881 
190, progesterone 100, and cortisol <0.1 (59). 
Table 1 shows the results of incubation of rat liver cytosol 
with and without ammonium sulfate purification. Note that at 4nM 
^H-R5020, R5020-specific binding is 389±77 fmoles/g liver in 
the unpurified preparation and 6.17±2.5 fmoles/g liver in the 
purified preparation. Ammonium sulfate purification (30%) resulted 
m a 98% reduction in specific binding at 4nM H-R5020. R5020 
competable binding as a percentage of total macromolecular binding 
was 44% in the unpurified preparation and 19% in the purified 
preparation. The initial incubating concentration of H-R5020 was 
chosen as 4nM, in the range of progesterone receptor . The 
for progesterone receptor was estimated by reference to values 
reported in the literature, summarized in Table 2. In the 
ammonium sulfate purified fractions note that incubation at 20nM, 
as opposed to 4nM H-R5020, produced roughly an eight fold increase 
in the amount of specifici binding recovered. The difference in 
specific binding recovered at the two incubating concentrations 
was statistically significant, p=.01. Note also that incubation 
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TABLE 1: Binding of 3H-R5020 to Rat Liver Cytosol 
Macromolecules with and without Purification 
Preparation d pm/.2 c c 
A. Unpurified 
[3H-R5020]= 4nM 
3H-R5020 + - 2430+ 67 
AR5020 1060+210 
AProgesterone (-1220+270) 
B. Purified 
[3H-R5020]= 4nM 
3H-R5020 + 
A R 5 0 2 0 
AProgesterone (- 
ACortisol ( - 
526+13 
102+40 
12+18 ) 
70+67 ) 
fmoles/g liver p 
889+24 
389+77 .01 
( -441+97 ) .025 
32.0 + . 83 
6.17+2.5 . 1 
(- .667+1.2) 
(-4.33+4.2) .1 
C . Purified 
[h-R5020]= 2 OnM 
3H-R5020 + 
AR5020 
Aprogesterone 
ACortisol 
2400 +160 
771 +200 
300 +190 
(- 95.+240) 
146 +9.8 
4 7 +12 
18.3 +12 
(- 5.83 + 14 ) 
.025 
Livers from 2 rats were homogenized in 6 vol(wt/vol) Progesterone 
assay buffer. One liver preparation, without purification, was 
incubated for 1 hour (as were all experimental preparations 
unless otherwise noted) at 4nM JH-R5020 in the presence of a) 
0 competitor, b) 200nM R5020, and c) 200nM progesterone. The 
other liver preparation was ammonium sulfate purified (30%), 
redissolved in 1/6 of the original volume, and split into two 
portions. The first portion was incubated at 4nM 3H-R5020 with 
a) 0 competitior, b) 200nM R5020, c) 200nM progesterone, and d) 
200nM cortisol. The second portion was incubated at 20nM 3H-R5020 
with a) 0 competitor, b) lOOOnM R5020, c) lOOOnM progesterone, 
and d) lOOOnM cortisol. The symbol A is used above to indicate 
the difference between two incubations, with and without a given 
competing compound. For all preparations macromolecular bound 
radioactivity was determined using gel filtration. Results are 
expressed as dpm/.2cc cytosol preparation or dpm/.2cc ammonium 
sulfate fraction and as femtomoles per milligram of liver. 
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TABLE 2: Values for of Progesterone Receptors in 
Cytosols of Various Tissues Obtained Using 3^-^5020 
Tissue & Source Id 
1) Estrogen primed, castrated 
adult female rat 
Uterus 
2) Estrogen primed, castrated 
adult female rat 
Uterus 
3) Estrogen primed & 
nonprimed, castrated adult 
female Bonnet Monkey 
Uterus 
Pituitary 
Brain 
6.8xl0-10 
1*10 -10 
2-3xl0"10 
t! II 
M f I 
4) Estrogen primed, castrated 
adult female rat 
Uterus 1 . 1 x 1 0 - 9 
5) Estrogen primed 4 
nonprimed, castrated, 
adrenalectomized 
adult f ema1e rat 
Uterus 
Pituitary 
HP S 
Cerebral Cortex 
Amygdala 
Midbrain 
Cerebellum 
2.9-3 . 2x10-1Q 
3.8-3.1 " 
2.8 
3 . 6-3.4 " 
2 . 7-2.6 " 
2 . 7-2 . 8 
3. 1-2.6 
6) Noneancerous, 
hysterectomy specimens 
from premenopausal 
women 
Reference 
Walters & Clark (60) 
Moguilewsky & 
Raynaud (48) 
MacLusky ej: a 1_. (49) 
Vu Hai & Milgrom (46) 
MacLusky & McEwen(61) 
End ome t rium 6.8xl0~10 Tsibris et a 1 . (62) 

o .... 
at 20nM H-R5020 increased the amount of specific binding recovered relative 
to total binding. In all subsequent experiments H-R5020 was employed at an 
incubating concentration of 20nM. 
Ammonium sulfate purification was employed principally to remove 
metabolizing enzymes found in unfractionated liver cytosol. These enzymes 
had, in a study by Eisenfeld et a_l.(4), been found to metabolize -^H-estradiol. 
Thirty percent was selected as the initial ammonium sulfate fraction on the 
basis of data in the literature suggesting that it was appropriate. Vu Hai 
3 
and Milgrom(46) found maximum precipitation of H-R5020-protein complexes in 
rat uterine cytosol at 20-30% saturation. 
In Table 3 the results of binding studies with rat uterine cytosol 
are reported. At 4 and 20nM ^h-R5020 statistically significant R5020-specific 
binding is recovered. In the experiments reported on here R5020-specific 
binding is equivalent to 82%, 31%, and 57% of observed total binding. The 
other ligands employed, progesterone and cortisol, competed for a fraction of 
binding equal to 66% and (-7%), repectively, of total binding. The pattern 
found above in ability of ligand to compete for binding sites is compatible 
with that expected for a progesterone receptor substance, R5020 > progesterone > 
cortisol. Incubation at 20nM 3h-R5020 did not markedly change the amount of 
R5020-competable binding as a percentage of total binding (57% at 20nM ^H-R5020 
v.s. 82% and 31% at 4nM -^H-R5020). At 20nM -^H-R5020, R5020 competable binding 
was determined to be 159 femtomoles/mg cytosol protein. 
Table 4 lists the results of binding studies performed with radioactive 
R5020 incubation performed prior to ammonium sulfate purification. Preincubation 
was tested as a possible method of improving detection of specific binding. 
The stability of progesterone receptors and hence their ability to survive the 
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TABLE 3: Binding of 3H-R5020 to Rat Uterine 
Cytosol Macromolecules 
Preparation dpm/.2cc fmoles/g uterus P 
fmoles/mg 
cytosol protein 
A. [3H-R5020]= 4nM 
3H-R5020 + - 
AR5020 
AProgesterone 
27,3001790 
22,5001830 
18,1001900 
9,980+290 
8,210+300 
6,610+330 
<.001 
<.001 
B. [3H-R5020]= 4nM 
3H-R5020 + - 
AR5020 
ACortisol 
4,4501110 
1,3601170 
(- 338+230 
1,630+39 
500163 
(- 120193) 
.005 
C. [3H-R5020]= 20nM 
3H-R5020 + - 
AR5020 
29,600+810 
16,800+1130 
10,9001300 
6,610+410 <.001 
280+7.6 
159111. 
Cytosol preparations were made from the uteri of 3 intact, female rats. 
One preparation was incubated for 1 hour at 4nM 3H-R5020 with the conditions; 
a) no competitor, b) 200nM R5020, c) 200nM progesterone. The second was 
incubated for 1 hour also at 4hM 3H-R5020 with the conditions; a) no 
competitor, b) 200nM R5020, c) 200nM cortisol. The third was incubated for 
1 hour at 20nM R5020 with a) no competitor and b) lOOOnM R5020. For all 
preparations macromolecular bound radioactivity was determined using gel 
filtration. Results are expressed as dpm/.2cc cytosol preparation, femtomoles 
per milligram liver, and, in C) above, as femtomoles per milligram protein of 
unpurified cytosol. 
Protein content: (preparation C only) unpurified cytosol=5.53 mg/cc. 
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conditions of assay conceivably might be improved if the receptor is 
loaded with steroid earlier in the assay. 
With a 30% ammonium sulfate cut R5020-competable binding is 34.1±11 
fmoles/g liver(22% of total binding) and is derived from a statistically 
significant difference. With a 40% ammonium sulfate(AS) cut R5020-competable 
binding is 121±36 fmoles/g liver in one preparation. In the other preparation 
with 40% AS cut R5020-competable binding is 176±13 fmoles/g liver(40% of 
total binding). With a 30% AS cut preincubation does not improve the total 
amount of specific binding recovered nor does it improve the amount of specific 
as a percentage of total binding recovered. See Table 1, preparation C 
(AR5020= 47±12 fmoles/g liver, 32% of total binding) and compare that result 
with the one obtained above with 30% AS cut (AR5020= 34.1±11 fmoles/g liver, 
22% of total binding). 
Results are also reported in this table as femtomoles/mg cytosol protein 
and femtomoles/mg protein in ammonium sulfate purified fraction. The value, 
fmoles/mg cytosol protein, is calculated here using the femtomoles as found 
in the ammonium sulfate purified fraction. This is divided by the concen¬ 
tration of protein as found in cytosol. This method may yield underestimation 
of specific binding per mg cytosol protein as compared with determining 
femtomoles directly from the disintegrations per minute of the cytosol fraction 
followed by division of that number by the concentration of cytosol protein. 
Ammonium sulfate purification may lower the recovery of specific binding 
present in cytosol. However it should be remembered that the specific binding 
detected in straight cytosol may not be of the same type as the specific 
binding present after AS purification. 
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TABLE 4: 
3 
Macromolecular Binding of H-R5020 in Rat Liver 
Cytosol Preparation with Incubation before Ammonium 
Sulfate Purification 
Preparation dpm/.2cc 
fmoles/g 
liver 
fmoles/mg 
cytosol 
protein 
fmoles/mg 
protein in 
purified fraction P 
A. Purified, 30% AS 
[3H-R5020]= 20nM 
JH-R5020 + - 2,170±150 158111 8.321.57 41.3+2.9 
AR5020 4671150 34.1111 1.791.57 7.912.9 .05 
AProgesterone 1,1501160 84112 4.411.63 20.319.8 .025 
B. Purified, 40% AS 
[^H-R5020]= 20nM 
H-R5020 + - 6,9801390 637136 32.111.8 62.113.5 
AR5020 5181150 121136 6.111.021 11.313.5 .1 
AProgesterone 7181530 65.5148 3.312.4 1014.6 
AR1881 (- 3471180) (- 8901470) (- 4.0912.2) (- 8.114.2) 
C. Purified, 40% AS 
[%-R5020] = 20nM 
JH-R5020 + - 4,8801140 445112 22.31.62 41.9+1.2 
AR5020 1,9301140 176113 00
 
00
 
1+
 ■> 16.811.2 .01 
AProgesterone 1,7301140 158112 7.891.62 16.311.2 .01 
AR1881 1,5201160 138114 6.911.71 14.811.3 .025 
Three intact, female rats were sacrificed and a cytosol preparation was made from 
each liver for a total of 3 preparations. The f^_rst preparation, A (rat from Camm 
suppliers) was incubated, in duplicate, at 20nM JH-R5020 with either a) no compe¬ 
titor, b) lOOOhM R5020, or c) lOOOnM progesterone. Each incubation was then indepen¬ 
dently ammonium sulfate purified (30%) and redissolved in 1/5 of the original 
cytosol volume. Preparations B (rat from Charles River suppliers) and C (rat from 
Camm suppliers) were independently, and each in duplicate, incubated at 20nM 
H-R5020 with either a) no competitor, b) lOOOhM R5020, c) lOOOnM progesterone, or 
d) lOOOnM R1881. Each incubation was then independently ammonium sulfate purified 
(40%) and redissolved in 1/4 of the original cytosol volume. For all preparations 
macromolecular bound radioactivity was determined using gel filtration. Results 
are expressed as dpm/.2cc ammonium sulfate fraction, femtomoles per gram liver, 
femtomoles per mg unpurified cytosol protein, and femtomoles per mg purified cytosol 
protein. 
Protein Concentrations (in mg/cc) 
Condition Preparation A Preparation B Preparation 
Unpurified 13.6 11.4 11.5 
Purified- 
incubated with 
a) no competitor 2.74 5.87 6.08 
b) lOOOnM R5020 2.66 5.81 6.15 
c) lOOOnM progesterone 2.54 6.28 6.42 
d) lOOOnM R1881 5.81 6.48 
4 9 
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In Table 5 are reported the results of incubations with varying 
ammonium sulfate cuts. Note that the only statistically significant competi¬ 
tion occurs with R5020 in the 40% AS cut, an amount equivalent to 170±17 
fmoles/g liver. Also in the 40% AS fraction there occurs the highest recovery 
of R5020-specific binding as a percentage of total binding; 28% versus 26% 
(50% AS), 15% (60% AS), and 10% (30% AS). This experiment indicates that 
in the liver cytosol preparation from non-estrogen primed intact, adult female 
rat a 40% ammonium sulfate precipitation yields the greatest amount of R5020- 
competable binding. 
Table 6 summarizes the results of an experiment wherein the incubate 
consisted of isolated, intact liver parenchymal cells. Progesterone receptors 
may be destroyed in the course of preparing the usual liver cytosol. Incubation 
in intact cells with steroid binding prior to homogenization may stabilize 
progesterone receptors to an extent that a greater number of them survive the 
subsequent steps of preparation. However, higher binding was not observed. 
The R5020-competable binding found, 50.3±25 fmoles/g cells, was derived from 
a non-statistically significant difference. Furthermore the absolute 
magnitude of specific binding found and the magnitude of specific binding as 
a percentage of total binding (34%) were no larger than had been found in 
previous experiments. 
Table 7 summarizes the results of an experiment involving estrogen 
primed rats. As discussed earlier it is believed that estrogen administration 
causes an increase in progesterone receptor number in some organs. In this 
experiment 2 rats were injected subcutaneously with lOOpg ethinyl estradiol 
once a day over a 3 day period for a total of 300yg ethinyl estradiol. 
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TABLE 5: Macromolecular Binding of 3K-R5020 in Rat Liver Cytosol 
Preparation after Precipitation of Independent Ammonium Sulfate 
Fractions; 30%, 40%, 50%, 60% 
fmoles/mg fmoles/mg 
fmoles/g cytosol protein in 
Fraction dpm/.2cc liver protein purified fraction p 
1 30% AS 
3U-R5020 + - 3,3601150 307114 15.21.7 72.813.3 
AR5020 3291160 30.1+15 1.491.72 7.213.5 
AProgesterone (- 3.591190) ( - .328117) ( - .01621.85) (- .078214.1) 
ACortisoI (- 2571210) ( - 23.5+19) ( - 1.161.94) (- 5.5814.5) 
2. 40% AS 
3K-R5020 + - 6,660179 610+7.3 30.11.34 56.41.67 
AR5020 1,8601190 170117 8.421.85 15.811.6 .0( 
AProgesterone 1,010+410 92.4138 4.5711.9 8.5513.5 .1 
ACortisoI 4801270 43.9124 2.1711.2 4.0712.3 
3. 50% AS 
3H-R5020 + - 5,4301560 497152 24.612.6 21.112.2 
AR5020 1,4101590 129+54 6.3812.7 5.4712.3 .1 
AProgesterone 7061640 64.5158 3.1912.9 2.7412.5 
ACortisoI 56.4+590 5.16154 .25512.7 .219+2.3 
4. 60% AS 
3E-R5020 + - 4,5701610 418+56 20.7+2.8 12.011.6 
AR5020 6711620 61.4157 3.0412.8 1.7611.6 
AProgesterone (- 2251610) ( - 52.8156) ( - 1.02+2.8) (- .59111.6) 
ACortisoI (- 4391750) ( - 40.2+68) ( 2.013.4) (- 1.16+2.0) 
A cytosol preparation was made from the livers of 2 intact, adult, female rats. 
This was split into four fractions and ammonium sulfate precipitated, 30%, 40%, 
50%, or 60%, with each fraction afterwards being redissolved in 1/4 of the original 
cytosol volume. The fractions were then independently incubated at 20nM 3H-R5020 
with either a) no competitor, b) lOOOnM R5020, c) lOOOnM progesterone, or 
d) lOOOnM cortisol. Macromolecular bound radioactivity was determined using gel 
filtration. Results are expressed as dpm/.2cc ammonium sulfate fraction, 
femtomoles per gram of liver, femtomoles per mg unpurified cytosol protein, and 
femtomoles per mg purified cytosol protein. 
Protein Concentrations: 
a) Ammonium sulfate fractions 30% 2.41 mg/cc 
40% 6.18 
50% 13.46 
60% 19.89 
b) Unpurified cytosol = 11.5±.56 mg/cc (This value is an average of 5 cytosol 
protein determinations from other 
experimental preparations.) 
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TABLE 6: Macromolecular Binding of 3H-R5020 
In Isolated, Intact Liver Parenchymal Cells 
dpm/.2cc 
fmoles/g 
liver 
fmoles/mg 
cytosol 
protein 
fmoles/mg 
protein in 
purified fraction 
3H-R5020 + - 1090190 148112 6.721.55 20.611.6 
AR5020 3721180 50.3125 2.2911.1 4.413.8 
A suspension of intact liver parenchymal cells was prepared as outlined in 
Materials and Methods. The suspension, divided into 12 portions, was 
incubated at 20nM 'VH-R5020, 6 portions with no competitor and 6 portions 
with lOOOnM R5020. After incubation the suspension was pooled into 4 fractions, 
2 that had been incubated with no competitor and 2 that had been incubated with 
the lOOOnM R5020. The 4 pools were then independently washed, homogenized, 
ultracentrifuged, and ammonium sulfate purified (40%, redissolved in 1/2.2 
of original volume). Macromolecular bound radioactivity was determined 
using gel filtration. Results are expressed as dpm/.2cc ammonium sulfate 
fraction, femtomoles per gram of cells, femtomoles per mg of unpurified 
cytosol protein, and femtomoles per mg purified cytosol protein. 
Protein Concentrations: 
a) Unpurified cytosol = 8.5 mg/cc 
b) AS purified cytosol 
i. those of incubate without competitor = 2.85 mg/cc 
ii. those of incubate with lOOOnM 3K-R5020 = 2.41 " 
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TABLE 7: Macromolecular 
Liver Cytosol Pre 
Days 
Binding of 3H-R5020 in Purified 
paration from Rats Primed for Three 
with Ethinyl Estradiol 
Preparation dpm/.2cc 
fmoles/g 
liver 
fmoles/mg 
cytosol 
protein 
fmoles/mg 
protein in 
purified fraction p 
1. Rat A 
3H-R5020 + - 3,0001150 274113 14.21.69 29.011.4 
AR5020 5261160 48.1115 2.501.77 5.09+1.6 
AProgesterone 4261190 38.9117 2.021.89 4.12+1.8 
AR1881 4871170 44.5115 2.311.80 4.71+1.6 
ACortisol (- 1871150) (- - 17.1114) (- .8891.71) (- 1.8111.4) 
2. Rat B 
3H-R5020 + - 3,9601170 362116 20.31.88 36.811.6 
AR5020 9281340 84.9131 4.7611.7 8.6213.1 
AProgesterone 3181290 29.1126 1.6311.5 2.9512.7 
AR1881 (- 1791310 (- - 16.4129) (- 9.2011.6) (- 1.67+2.9) 
ACortisol (-1,0721350) (- - 98.0+32) (- 5.49+1.8) (- 9.95+3.2) 
Two intact, adult, female rats were subcutaneously injected with 100 yg ethinyl 
estradiol once a day over a 3 day period for a total of 300 yg ethinyl 
estradiol. Twenty four hours after the last injection they were sacrificed 
and liver cytosol preparations were made from each. These were ammonium sulfate 
purified (40%, redissolved in 1/4 original volume) and then incubated at 20nM 
^H-R5020 with a) no competitor, b) lOOOnM R5020, c) lOOOnM progesterone, 
d) lOOOnM R1881, and e) lOOOnM cortisol. For both groups of preparation, 
macromolecular binding was determined using gel filtration. Results are 
expressed as dpm/.2cc ammonium sulfate fraction, femtomoles per gram of liver, 
femtomoles per mg of unpurified cytosol protein, and femtomoles per mg purified 
cytosol protein. 
Protein Concentrations: 
Rat A) i. unpurified cytosol = 11 
ii. ammonium sulfate fraction = 5.4 
Rat B) i. unpurified cytosol = 10.2 
ii. ammonium sulfate fraction = 5.6 
mg/cc 
II 
VI 
IV 
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Walters and Clark (60) found a statistically significant priming effect in 
rat uterus with just 1 to 2 pg of estradiol-176 per rat. MacLusky and 
McEwen (61) found a statistically significant priming effect in several organs 
with 3 days treatment of 15 yg/day of estradiol benzoate per rat. Vu Hai and 
Milgrom (46) found an optimum priming response from progesterone receptors 
of rat uterus with administration of 5 yg estradiol per rat, per day for 2 days. 
After priming, the 2 rats were sacrificed and binding was determined 
in the ammonium sulfate purified liver cytosol fractions. In one preparation 
R5020-competable and R1881-competable binding reaches statistical significance. 
However, the magnitude of the R5020-specific binding found and the 
magnitude of the latter as a percentage of total binding (18% in rat A, 
23% in rat B) are no greater than those found in previous experiments. 
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DISCUSSION 
These experiments indicate that low levels of macromolecule 
which specifically binds R5020 may be present in rat liver. The 
competitive ligands used, R5020, progesterone, R1881, and cortisol 
3 
demonstrate differing abilities to compete for the binding of H-R5020. 
The pattern of competition seen, R5020 > progesterone > R1881 > cortisol, 
is very similar to the pattern of binding affinities, highest to lowest - 
R5020 > R1881 > progesterone > cortisol, exhibited by these ligands for 
uterine progesterone receptor from estrogen-primed rabbits (59). In 
uterine cytosol of estrogen primed castrated adult female rats, Vu Hai and 
Milgrom (46) found R5020 to be of higher affinity for progesterone 
receptor than progesterone itself. Cortisol, they found, exhibited no 
affinity. The R5020 specific binding of rat liver cytosol thus 
3 
demonstrates a varying affinity at 20 nM H-R5020 for competitive ligands 
that resembles that of progesterone receptors found in other tissues. 
The R5020 binding moiety of rat liver cytosol can however be termed 
only a putative progesterone receptor for only the property of hormone 
specificity has been demonstrated. Yet to be demonstrated are the 
properties of high affinity, finite binding capacity and correlation 
with tissue response. 
It is interesting to note that in a number of the experiments 
performed with rat liver cytosol cortisol demonstated a negative 
competitive effect which in one experiment (see Table 7, rat B) 
attained statistical significance. The presence of cortisol in an 
incubation may increase the availability of R5020 for binding principally 
to nonspecific sites. A possible explanation for this involves presuming 
the existance of two types of nonspecific sites, one with a relatively 
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higher affinity for cortisol than for R5020 and the other, present in 
greater number, with a lesser affinity for R5020 and an even lesser 
affinity for cortisol (affinity site 1 cortisol > affinity site 1 R5020 > 
affinity site 2 R5020 > affinity site 2 cortisol). When in the presence 
of excess cortisol, R5020 will not bind at all to site 1, increasing 
its own availability for binding to site 2. 
In these experiments the amount of R5020 specific binding is low. 
It attained statistical significance in preparations from 5 different rat 
livers. It failed to gain significance in the preparations from 3 other 
rat livers. Excluded from consideration here is the one preparation of 
intact liver parenchymal cells. If one considers data from the literature 
(see Table 8), the amount of R5020 specific binding found, 34-170 fmoles/g 
tissue or 1.8-8.8 fmoles/mg cytosol protein (40% AS, [^H-R5020] = 20 nM), 
is less than that found in almost all tissues. It is comparable to the 
level of specific binding found in non-estrogen-primed Bonnet Monkey 
pituitary and hypothalamus/preoptic area (8 fmoles/mg cytosol protein) 
and to that found in non-primed adult rat cerebellum (5.9 fmoles/mg 
cytosol protein). To be kept in mind is the fact that the values from 
the literature represent the results of analysis according to the method 
of Scatchard, involving incubations over a range of concentrations of 
3 
H-R5020. The amount of R5020 specific binding reported in this work is 
3 
derived from assays at principally one concentration of H-R5020, 20 nM, 
assumed to be saturating. 
No effect on amount of R5020 specific binding was found with priming 
of 300 yg of ethinyl estradiol. In the work of other investigators 
(see Table 8) estrogen priming with agents such as moxestrol (48), 
estradiol benzoate (61), and 178-estradiol (49) led to marked increases 
in amount of specific binding detected in other organs. 
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TABLE 8: R5020 Competable Binding in Cytosol of 
Various Tissues when Incubated with 3h-R5020 
Tissue & Source Number of Sites Reference 
1) 
p moles/g tissue 
Non-primed Estrogen primed 
Castrated adult female 
rat 
Uterus ^4.5 35.811.3 
Pituitary ^2 10.91.5 
Hypothalamus ^ .5 .911.04 
Cerebral cortex % . 9 .621.1 
Moguilewsky & 
Raynaud (48) 
2) Castrated, adrenalectomized 
adult female rat 
Uterus 
Pituitary 
Cerebral cortex 
Cerebellum 
fmoles/mg cytosol protein 
Non-primed Estrogen primed 
546±138 
34.9±3.7 
26.013.3 
5.9+1.6 
31201628 
294126 
24.5+2.8 
7.112.1 
MacLusky & 
McEwen 
3) Castrated adult female 
bonnet monkey 
Uterus 142+11 
Pituitary 812 
Hypothalamus 
& preoptic area 8 
4) Noncancerous 
hysterectomy specimens 
from premenopausal 
women 
Endometrium 50-3,500 
627161 
9017 
14 
MacLusky 
et al. 
Tsibris 
et al. 
(61) 
(49) 
(62) 
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In this investigation R5020 specific binding was found in uterine 
cytosol in amounts ranging from 500 to 6,160 fmoles/g uterus (see Table 3). 
This is 5 to 60x the amount found in liver cytosol preparations. At 
20 nM ^H-R.5020, R5020-specific binding was determined to be 6,160 fmoles/g 
uterus or 159 fmoles/ng cytosol protein. The value 6,160 fmoles/g uterus 
is quite comparable to the value 4,500 fmoles/g uterus obtained by Moguilewsky 
and Raynaud (48) in uterus of non-estrogen primed castrated adult female 
rat (see Table 8). Note also that the value of 159 fmoles/mg cytosol 
protein is roughly 3 fold less than that found by MacLusky and McEwen (61) 
in cytosol of non-primed castrated adrenalectomized adult female rat (see 
also Table 8). In the same preparation their value for number of sites in 
uterus was 16x, 21x, and 93x higher than those found in pituitary, cerebral 
cortex, and cerebellum respectively. 
These results must not be regarded as conclusive. The assays 
performed in this investigation were performed at only one assumed, 
3 
saturating, concentration of H-R5020. The methods used herein may not 
adequately protect the putative rat liver progestin receptor prior to 
isolation for determination of macromolecular binding. However, several 
alternative methods were employed in this investigation to stabilize a 
progestin binder. These included preincubating cytosol with steroid 
prior to ammonium sulfate purification and incubation of intact liver 
parenchymal cells prior to homogenization. Neither method resulted in 
an increase in R5020 specific macromolecular binding. The buffer system 
used in these experiments, phosphate-glycerol, has been exployed success¬ 
fully by other investigators for isolation of progesterone receptors, (62), 
(56). This exact buffer is currently employed for progesterone receptor 
assays in human breast carcinomas in the Yale Gynecology-Endocrine 
Laboratory. Another possible source of error in these experiments is 
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metabolism. Metabolism could possibly significantly reduce the amount 
3 
of H-R5020 available for binding and thereby produce spuriously low 
levels of macromolecular binding. This type of artifact was checked 
for by use of thin layer chromatography and was found not to be 
present in the experiments reported on in Table 4 - parts B and C, 
Table 5, and Table 7. 
Although progestin-unique oral contraceptive side effects may occur 
in the human,it is by no means certain that a progestin receptor will 
be found in rat liver. It has been assumed here that the presence of 
progestin-unique oral contraceptive side effects, because of the likely 
involvement of liver in producing such effects, implies the presence of 
progestin receptor in human liver. This is not necessarily true. For 
example, progesterone mediated effects may occur via an interaction with 
liver estrogen receptor. Estrogen receptor has been isolated in rat 
liver (2)> (3), (4), (5). It is further assumed that the putative 
progestin receptor if present in the liver of one mammal, the human, 
will be present in the liver of another mammal, the rat. If however such 
a receptor were found in rat liver,, this could be experimentally studied. 
The results may Suggest approaches to minimizing progestin-mediated 
oral contraceptive side effects via altering progestin-receptor interactions. 
In summary, a low, and not always statistically significant, level 
of R5020 specific binding activity has been isolated in rat liver cytosol. 
This does show ligand specificity as expected of a progestin binding 
substance but does not respond to estrogen priming as demonstrated in 
other progestin binders. Further work in this area could include 
additional efforts to stabilize progestin binder in cytosol. Further 
experimentation with an intact cell preparation appears justified in view 
of an inadequate check in this study for metabolism of H-R5020. A series 
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3 
of incubations at differing concentrations of H-5020 would allow 
determination of putative receptor K^. Finally, liver preparations 
in other animals may prove more fruitful in yielding greater amounts 
of progestin binder. 
60 

REFERENCES 
1. Department of Medical and Public Affairs, The George Washington 
University Medical Center, Oral Contraceptives Population Report, 
Series A2: "Advantages of Orals Outweigh Disadvantages," pp29-51, 
1975 cited in Durand, J. L., "Clinical Pharmacology of the 
Steroid Oral Contraceptives," Adv. Internal Medicine 24:97, 1979. 
2. Eisenfeld, A. J., Aten, R. F., and Mitchell, J. W., "Oral 
Contraceptives - Possible Mediation of Side Effects via an Estrogen 
Receptor in Liver," Biochemical Pharmacology 27:2571, 1978. 
3. Eisenfeld, A. J., Aten, R. F., Weinberger, M., Haselbacher, G., 
Halpern, K., "Estrogen Receptor in the Mammalian Liver," Science 
191:862, 1976. 
4. Eisenfeld, A. J., Aten, R. F., Haselbacher, G. K., and Halpern, K., 
"Specific Macromolecular Binding of Estradiol in the Mammalian 
Liver Supernatant," Biochemical Pharmacology 26:919, 1977. 
5. Eisenfeld, A. J., Krakoff, L., and Aten, R. F., "Developmental 
Correlation of Higher Levels of Estrogen Binding by Macromolecules 
in Rat Liver Supernatant and of Increases in Plasma Renin Substrate 
after Estrogen Administration," Biochemical Pharmacology 26:923, 1977 
6. Durand, J. L., and Bressler, R., "Clinical Pharamcology of the 
Steroid Oral Contraceptives," Advances in Internal Medicine 24:97, 
1979. 
7. McQueen, E. G., "Hormonal Steroid Contraceptives: A Further Review 
of Adverse Reactions," Drugs 16:322, 1978. 
8. Andrews, W. C., "Oral Contraception - Physiologic and Pathologic 
Effects," in Obstetrics and Gynecology Annual edited by Ralph M. Wynn 
7:325, 1978. 
9. Royal College of General Practitioners: Oral Contraceptives and 
Health: an Interim Report from the Oral Contraceptive Study of the 
Royal College of General Practitioners^(New York: Pitman), 1974. 
10. Collaborative Group for the Study of Stroke of Young Women: "Oral 
Contraception and increased risk of cerebral ischemia or thrombosis," 
New Engl. J. of Med. 17:871, 1973. 
11. Beral, V. , "Mortality Among Oral - Contraceptive Users - Royal 
College of General Practitioners Oral Contraceptive Study," 
Lancet 2:728, 1977. 
12. Vessey, M. P., McPherson, K., Johnson, B., "Mortality amount Women 
Participating in the Oxford/Family Planning Association Contraceptive 
Study," Lancet 2:731, 1977. 
13. Jick, H., Dinan, B., Herman, R., Rothman, K. J., "Myocardial 
Infarction and Other Vascular Diseases in Young Women," JAMA 240:2548 
1978. 
61 
- 
.. 
, 
14. Klatskin, G., "Hepatic Tumors: Possible Relationship to Use of 
Oral Contraceptives," Gastroenterology 73:386, 1977. 
15. Bennion, L. J., Ginsberg, R. L., Garnick, M. B., and Bennett, P. H., 
"Effects of Oral Contraceptives on the Gall bladder Bile of Normal 
Women," New England Journal of Medicine 294:189, 1976. 
16. "Approval of Depo-Provera for Contraception Denied," FDA Drug 
Bulletin 8:10, 1978. 
17. Aarskog, D., "Maternal Progestins as Possible Cause of Hypospadias," 
N ew England Journal of Medicine 300:75, 1979. 
18. Medical Letter, "Serious Adverse Effects of Oral Contraceptives and 
Estrogens," 18:21, 1976. 
19. Spellacy, W. N., Birk, S. A., "The Effect of Intrauterine Devices, 
Oral Contraceptives, Estrogens, and Progestogens on Blood Pressure," 
Am. J. of Obstetrics & Gynecology 112:912, 1972. 
20. Weir, R. J., Fraser, R., McElwee, G., Morton, J. J., Treet, M., and 
Young, J., "The effect of estrogen-progestin oral contraceptives on 
blood pressure and on the renin-angiotensin-aldosterone system," in 
Fregly, M. J., and Fregly, M. S. (editors): Oral Contraceptives and 
High Blood Pressure, Gainesville, Florida 1974, Dolphin Press p68. cited 
in Hall, W. D., Douglas, M. B., Blumenstein, B. A., and Hatcher, R. A., 
"Blood Pressure and Oral Progestational Agents," American J. of Obstetrics 
and Gynecology 136:344, 1980. 
21. Edgren, R. A., and Sturtevant, F. M., "Potencies of Oral Contraceptives," 
American J. of Obstetrics and Gynecology 125:1029, 1976. 
22. Laragh, J. H., "Oral Contraceptive-Induced Hypertension - Nine Years 
Later," Am. J. of Obstetrics and Gynecology 126:141, 1976. 
23. Meade, T. W., Charkrabarti, R., Haines, A. P., Howarth, D. J. Noith, 
W. R. S., and Stirling, Y., "Hoemostatic, Lipid and Blood-Pressure Profiles 
of Women on Oral Contraceptives Containing 50 yg or 30 yg Oestrogen," 
The Lancet 2:948, 1977. 
24. Royal College of General Practitioners Oral Contraceptive Study, 
"Effect on Hypertension and Benign Breast Disease of Progestagen 
Component in Combined Oral Contraceptives," Lancet 1:624, 1977. 
25. Hall, W. D., Douglas, M. B., Blumenstein, B. A., Hatcher, R. A., 
"Blood Pressure and Oral Progestational Agents: A Prospective Study 
of 119 Black Women," Am. J. Obstetrics & Gynecology 136:345, 1980. 
26. Inman, W. H. W., Vessey, M. P., Westerholm, B., Engelund, A., 
"Thromboembolic Disease and the Steroidal Content of Oral 
Contraceptives. A Report to the Committee on Safety of Drugs," 
British Medical Journal, ii:203, 1970. 
62 
* 
' 
27. Howie, P. W., Mallinson, A. C., Prentice, C. M., Hoine, C. H. W., 
and McNicol, G. P., "Effects of Combined Oestrogen-Progestogen Oral 
Contraceptives, Oestrogen, and Progestogen on Anti plasmn and Anti 
thrombin Activity," Lancet 2:1329, 1970. 
28. Poller, L., Thomson, J. M., Thomas, W., Wray, C., "Blood Clotting 
and Platelet Aggregation during Oral Progestogen Contraception - 
a Follow-up Study," British Medical Journal 1:705, 1971. 
29. Poller, L., Thomson, J. M., Thomas, P. W., "Effects of Progestogen 
Oral Contraception with Norethisterone on Blood Clotting and Platelets,' 
British Medical Journal iv:391, 1972. 
30. Mink, I. B., Courey, N. G., Moore, R. H., Ambrus, C. M., Ambrus, J. L., 
"Progestational Agents and Blood Coagulation IV. Changes Induced by 
Progestogen Alone," Am. J. of Obstetrics & Gynecology 113:739, 1972. 
31. Ambrus, J. L., Mink, I. B., Courey, N. G., Niswander, K. H., Moore, 
R. H., Ambrus, C. M., and Lillie, M. A., "Progestational agents and 
blood congulation VII: Thromboembolic and other complications of 
oral contraceptive therapy in relationship to pretreatment levels of 
blood coagulation factors: Summary report of a 10 year study," 
Am. J. Obstetrics 125:1057, 1976. 
32. Korson-Bengtsen, K., and Larsson, B., "Effect on Blood Coagulation 
and Fibrinolysis in Women Using Norethisterone or a Combination of 
Ethinyloestradiol and Quingestional," Gynecol Obstet Invest 9:312, 1978 
33. Spellacy, W. N., "A Review of Carbohydrate Metabolism and the Oral 
Contraceptives," Am. J. of Obstet. & Gynecology 104:449, 1969. 
34. Kalkhoff, R. K., "Effects of Oral Contraceptive Agents and Sex Steroids 
on Carbohydrate Metabolism," Annual Review of Medicine 23:429, 1972. 
35. Beck, P., "Contraceptive Steroids: Modifications of Carbohydrate and 
Lipid Metabolism," Metabolism, 22:841, 1973. 
36. Spellacy, W. N., Buhi, W. C., Birk, S. A., McCreary, S. A., "Metabolic 
Studies in Women Taking Norethindrone for 6 months Time (Measurement 
of Blood Glucose, Insulin, and Triglyceride Concentrations)," 
Fertility and Sterility 24:419, 1973. 
37. Spellacy, W. N., Newton, R. E., Buhi, W. C., Birk, S. A., "Carbohydrate 
and Lipid Studies During Six Months' Treatment with Megestrol Acetate," 
American Journal of Obstetrics & Gynecology 116:1074, 1973. 
38. Weikel, J. H., Jr., Nelson, L. W., and Reno, F. E., "A four-Year 
Evaluation of The Chronic Toxicity of Megestrol Acetate in Dogs," 
Toxicology and Applied Pharmacology 33:414, 1975. 
39. Goldman, J. A., "Effect of Ethynadiol Diacetate and a Combination-Type 
Oral Contraceptive Compound on Carbohydrate Metabolism," Diabetologia 
13:89, 1977. 
63 
‘ 
40. Beck, P., "Effect of Progestins on Glucose and Lipid Metabolism," 
Annals of N, Y. Acad, of Sciences 286:434, 1977. 
41. Brown, M. S., Goldstein, J. L., "Disorders of Lipid Metabolism," 
Chapter 100 in Harrison's Principles of Internal Medicine, 9th edition, 
edited by Isselbacher, K. J., Adams, R. D., Braunwald, E., Petersdorf, 
R. G., and Wilson, J. D., McGraw-Hill Book Company, New York, 1980, 
pp507-509. 
42. Bradley, D. D., Wingerd, J., Petitti, D. B., Krauss, R. M., and 
Ramcharan, S., "Serum High-Density-Lipoprotein Cholesterol in Women 
Using Oral Contraceptives, Estrogens and Progestins." New England J. 
of Medicine 299:17, 1978. 
43. Chan, L., O'Malley, B. W., "Steroid Hormone Action: Recent Advances," 
Annals of Internal Medicine 89 (part 1):694, 1978. 
44. J'dnne, 0., Kontula, K., Vihko, R. , Feil, P. D., Bardin, C. W. , 
"Progesterone Receptor and Regulation of Progestin Action in Mammalian 
Tissues," Medical Biology 56:225, 1978. 
45. Leavitt, Wendell, W., Chen, T. J., Do., Y. S., Carlton, B. D., 
Allen, T. C., "Biology of Progesterone Receptors," in Receptors and 
Hormone Action, Volume II edited by Bert W. O'Malley and Lutz 
Birnbaumer, Academic Press, New York, 1978, ppl57-188. 
46. Vu Hai, M. T., Milgrom, E. "Characterization and Assay of The 
Progesterone Receptor in the Rat Uterine Cytosol," J. Endocrinology 
76:21-31, 1978. 
47. Schreiber, J. R. and Hsueh, A. J. W., "Progesterone 'Receptor' in 
Rat Ovary." Endocrinology 105:915, 1979. 
48. Moguilewsky, M., Raynaud, J. P., "Estrogen-Sensitive Progestin- 
Binding Sites in the Female Rat Brain and Pituitary," Brain Research 
164:165, 1979. 
49. MacLusky, N. J., Lieberburg, I., Krey, L. C., and McEwen, B. S., 
"Progestin Receptors in the Brain and Pituitary of the Bonnet Monkey 
(Macaca radiata): Differences between the Monkey and the Rat in the 
Distribution of Progestin Receptors," Endocrinology 106:185, 1980. 
O 
50. Green, I. C., Howell, S. L., Perrin, D., "Binding of H-Progesterone 
by Isolated Rat Islets of Langerhans," Diabetologia 15:349, 1978. 
51. Tamaya, T., Motoyama, T., Ohono, Y., Ide, N., Tsurusaki, T., Okada, H., 
"Estradiol-17-8; Progesterone and 5a-Dihydrotestosterone Receptors of 
Uterine Myometrium and Myoma in the Human Subject," J. of Steroid 
Biochemistry 10:615, 1979. 
52. Kreitmann, B., Bugat, R., and Bayard, F., "Estrogen and Progestin 
Regulation of the Progesterone Receptor Concentration in Human 
Endometrium," J. of Clinical Endocrinology and Metabolism," 49: 
926, 1979. 
64 
-• 
* 
- 
' 
; 
53. Allegra, J. C., Lippman, M. E., Thompson, E. B., Simon, R., 
Barlock, A., Green, L., Huff, K. K., Do, H. M. T., and Aitken, S. C., 
"Distribution, Frequency and Quantitative Analysis of Estrogen, 
Progesterone, Androgen, and Glucocorticoid Receptors in Human 
Breast Cancer," Cancer Research 39:1447, 1979. 
54. MacDonald, J. S., Lippman, M. E., Wolley, P. V., Petrucci, P. P., 
and Schein, P. S., "Hepatic Estrogen and Progesterone Receptors in 
an Estrogen-Associated Hepatic Neoplasm," Cancer Chemotherapy and 
Pharmacology 1:135, 1978. 
55. Stumpf, W. E., Sar, M., "Autoradiographic Localization of Estrogen, 
Androgen, Progestin, and Glucocorticosteroid in 'Target Tissues' 
and 'Non target Tissues,' " in Receptors and Mechanism of Action of 
Steroid Hormones edited by Dr. Jorge R. Pasqualini, Marcel Dekker, 
Inc., New York, 1976, pp41-84. 
56. Horwitz, K. B., McGuire, W. L., Pearson, 0. H., and Segaloff, A., 
"Predicting Response to Endocrine Therapy in Human Breast Cancer: 
A Hypothesis," Science 189:727, 1975. 
57. Lowry, 0. H., Rosenbrough, N. J., Farr, A. L., and Randall, R. J., 
"Prolactin Measurement with the Folin Phenol Reagent," J. Biol. Chem. 
193:265, 1951. 
58. Dickson, R. B., and Eisenfeld, A. J., "Estrogen Receptor in Rat 
Liver: Translocation to the Nucleus in Isolated Parenchymal Cells," 
Endocrinology 105:627, 1979. 
59. Raynaud, J. P., "R5020, a Tag for the Progestin Receptor," in 
Progesterone Receptors in Normal and Neoplastic Tissues edited by 
McGuire, W. L., Raynaud, J. P., and Baulieu, E. E., Raven Press, 
New York, 1977, pp9-21. 
60. Walters, M. R. and Clark, J. H., "Nuclear and Cytoplasmic Progesterone 
Receptors in The Rat Uterus: Effects of R5020 and Progesterone 
on Receptor Binding and Subcellular Compartmentalization," in 
Progesterone Receptors in Normal and Neoplastic Tissues edited by 
McGuire, W. L., Raynaud, J. P., and Baulieu, E. E., Raven Press, 
New York, 1977, pp271-285. 
61. MacLusky, N. J. and McEwen, B. S., "Progestin Receptors in Rat 
Brain: Distribution and Properties of Cytoplasmic Progestin- 
Binding Sites," Endocrinology 106:192, 1980. 
62. Tsibris, J. C., Cazenave, C. K., Cantor, B., Notelovitz, M., 
Kalra, P. S., Spellacy, W. N., "Distribution of Cytoplasmic 
Estrogen and Progesterone Receptors in Human Endometrium," Am. J. 
of Obstetrics & Gynecology 132:449, 1979 
65 
- 


YALE MEDICAL LIBRARY 
Manuscript Theses 
Unpublished theses submitted for the Master’s and Doctor’s degrees and 
deposited in the Yale Medical Library are to be used only with due regard to the 
rights of the authors. Bibliographical references may be noted, but passages 
must not be copied without permission of the authors, and without proper credit 
being given in subsequent written or published work. 
This thesis by has been 
used by the following persons, whose signatures attest their acceptance of the 
above restrictions. 
NAME AND ADDRESS DATE 

